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Abstract
The recreational use of “emerging drugs” of abuse (e.g., Spice, “bath salts”) is a growing
problem that has taken root in the United States and is increasingly recognized as a public health
concern (National Institute on Drug Abuse, 2012). However, there is a gap in knowledge
regarding the level of risk that individuals associate with the use of these substances. In addition,
there is a critical knowledge gap regarding how young adults utilize anecdotal and statistical
information when evaluating the risk of using emerging drugs. The present study addresses these
gaps in knowledge in two specific aims. First, the present study investigates the perceived level
of harm that young adults associate with the use of novel drugs. Second, the present study
investigates how young people evaluate the risks associated with the use of novel drugs when
they are given both statistical information about the risks associated with the use of novel drugs
and anecdotal reports describing positive and negative drug experiences with using novel drugs.
The present study has implications for identifying strategies that improve risk communication
about the dangers of using emerging drugs of abuse.
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Chapter 1: Introduction
1.1

OVERVIEW
The recreational use of “emerging drugs” of abuse (e.g., Spice, “bath salts”) is a growing

problem that has taken root in the United States and is increasingly recognized as a public health
concern (National Institute on Drug Abuse, 2012). Despite the health threats associated with the
use of emerging drugs, little is known regarding the level of risk that individuals associate with
the use of many of these substances. Moreover, few social marketing campaigns are designed to
inform youth about the health risks associated with using these emerging substances, often
leaving young people to learn about the hazards of these substances through friends or from
anecdotal reports posted on online discussion forums (National Institute on Drug Abuse, 2012).
Such sources may provide inconsistent information with some friends reporting negative
experiences and others reporting positive experiences. Notably, studies investigating how young
adults reconcile positive and negative anecdotal information when evaluating the risk of using
emerging drugs of abuse are lacking.
Moreover, there is a gap in knowledge addressing how young people weigh the relative
importance of anecdotal information and statistical information in the evaluation of risk for using
emerging drugs. Although many studies have investigated the impact of narrative and statistical
information on risk perceptions, nothing is known about how young adults weigh the relative
importance of narrative and statistical evidence when young adults evaluate the risks associated
with the use of emerging drugs of abuse.
In short, there is a critical knowledge gap regarding the perceived level of risk that young
adults associate with using recreational emerging drugs as well as a critical gap in knowledge
regarding how young adults utilize anecdotal and statistical information when evaluating the risk
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of using emerging drugs. Therefore, the proposed research has two aims. First, the study seeks to
investigate the perceived level of risk that young adults associate with the use of novel drugs.
Importantly, prior studies have demonstrated that as perceived risk increases there is a
concomitant decrease in drug use (Bachman, 1988), suggesting that communications designed to
increase the perceived risk of using novel substances may be an effective prevention strategy.
Second, the study seeks to investigate how young people evaluate the risks associated with the
use of novel recreational drugs when they are given both statistical information about the risks of
using these drugs as well as conflicting anecdotal reports that describing positive drug
experiences. In other words, the study seeks to answer the following question: “Do anecdotal
reports describing drug experiences bias how individuals weigh base-rate information that
highlight the risks of using emerging drugs of abuse?” The findings from the proposed study
should help to identify strategies for improving risk communications about the dangers of
emerging drug use.
1.2

EMERGING DRUGS OF ABUSE
Every generation faces its own emerging recreational drugs of abuse. For example, the

use of PCP (i.e., angel dust) and nitrite inhalants (i.e., poppers) was prominent in the 1970’s; the
use of crack and methamphetamine (i.e., ice) was prominent in the 1980’s, and the use of ecstasy
and other club drugs (e.g., MDMA, GHB) has increased in the past few decades (Johnston, O’
Malley, Bachman, Schulenburg, 2010). More recently, there has been an increase in the use of
synthetic drugs of abuse. For example, the use of synthetic marijuana (e.g., Spice, K2, Genie)
containing synthetic cannabinoids and synthetic amphetamines (also known as “bath salts”)
containing synthetic cathinones has increased, and the use of these substances is increasingly
recognized as a public health concern (National Institute on Drug Abuse, 2012). Notably, the use
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of these latter substances increased rapidly when the drugs were initially introduced and then
drug use appeared to decline with time, as indexed by calls made to U.S, poison control centers.
For example, in 2010, there were 2,906 calls made to U.S. Poison Control Centers regarding the
use of synthetic marijuana (e.g., Spice, K2). By 2011, that number had more than doubled to
6,968 (American Association of Poison Control Centers, 2014). In 2012, however, the number
dropped to 5,230 and, in 2013, it dropped even further to 2,657 (American Association of Poison
Control Centers, 2014). Similarly, the use of synthetic amphetamines marketed as “bath salts”
increased rapidly initially and only more recently has the use of synthetic amphetamines begun
to taper off. For example, in 2010, there were 304 calls made to U.S. poison control centers. By
2011, that number rose to 6,137 representing a more than a 20 fold increase in a single year In
2012, however, the number dropped to 2,691 and, in 2013, it dropped to 995 cases (American
Association of Poison Control Centers, 2014).
In a recent review Coulson and Caulkins (2011) identified 63 emerging substances that
were subject to legal restrictions over the last 40 years in countries such as the United States, the
United Kingdom, and New Zealand. The majority of these substances could be subsumed under
the following drug classes: phenethylamines, piperazines, tryptamines, phencyclidines,
pyrrolidines, amphetamines, and benzodiazepines. The authors note that the rate of emergence of
novel drugs with a high abuse potential has remained steady since 1971. As such it is reasonable
to expect that the ongoing pattern of newly emerging drugs with a high abuse potential will
continue and is likely to remain a danger for years to come so long as there is a demand for novel
drug candidates that are unregulated, that mimic currently restricted drugs, and are undetectable
by commercial drug screening procedures.
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In order to identify emerging drugs of abuse that were not included in the above report a
literature search was conducted using the following keyword search terms: “legal highs,”
“emerging drugs,” “novel drugs of abuse,” and “designer drugs.” The following databases were
searched: Health and Psychosocial Instruments, Health Source: Nursing and Academic Edition,
MedLine, Psychology and Behavioral Sciences Collection, PsychInfo, and ERIC. Keyword
search terms were restricted to peer-reviewed journals that published papers between the years
2000-2012. The search for the terms “legal highs,” “emerging drugs,” and “novel drugs of
abuse” was conducted on May 30th, 2012. The search for the term “designer drugs” was
conducted on June 18th, 2012. A total of 175 relevant articles were identified (removing
duplicates). A list of emerging drugs and associated drug classes as a result of this search are
listed below (see Table 1).

Table 1: Compendium of Emerging Drugs (in bold), Traditional Drugs, and Associated Drug
Classes
“Street” nomenclature

Drug Type and Drug Name
Phenylethylamines
Amphetamine
Methamphetamine
Β-3,4,5-trimethoxyphenethylamine (mescaline)
3,4-methylenedioxy-N-ethylamphetamine (MDEA)
3,4-methylenedioxy-N-methylamphetamine (MDMA)
4-bromo-2,5-dimethoxyphenethylamine (2C-B)
2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2)
2,5 –dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7-T7)
4-methylthioamphetamine (4-MTA)
4-methyl-2,5-dimethoxyamphetamine (DOM)
4-bromo-2,5-dimethoxyamphetamine (DOB)
Piperazine-derivatives
N-benzylpiperazine (BZP)
1-(3,4-methylenedioxybenzyl)piperazine (MDBP)
1-(3-chlorophenyl)piperazine (mCPP)
1-(4-methoxyphenyl)piperazine (MeOPP)
1-(3-trifluoromethylphenyl)piperazine (TFMPP)
4

“Speed”
“Meth”
“Love Drug,” “Eve”
“Ecstasy,” “X”
“Nexus”, “Bromo”
“Tripstasy,”
“A2”
-

Tryptamines and related synthetics
4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin)^
4-OH N,N-dimethyltryptamine (psilocin)
5-OHdimethyltryptamine (bufotenine)
N,N-dimethyltryptammine (DMT)
5-methoxy- N,N-dimethyltryptammine (5-MeO-DMT)
N,N-alpha-methyltryptamine (AMT)
5-methoxy- N,N-alpha-methyltryptamine (5-MeO-AMT)
N,N-dipropyltryptamine (DPT)
5-methoxy- N,N-diisopropyltryptamine (5-MeO-DIPT)
Opioid Kappa Receptor Agonist
Salvia divinorum

“Salvia”

Sedative-Hypnotic
γ-hydroxybutyric acid (GHB)

-

Glutaminergic NMDA Receptor Antagonists
Phencyclindine (PCP)
Ketamine
Dextropmethorphan (DXM)

“Angel Dust”
“Special K”
“Robo-tripping”

Synthetic Marijuana (i.e., synthetic cannabinoids)
HU-210*; JWH-018*; JWH-073*; JWH-250*; CP47,497

Collectively referred
to as “Spice”

Synthetic Amphetamines (i.e., substituted cathinones)
4-methlymethcathinone (Mephedrone)
“bath salts”
Note: emerging drugs noted in bold; *denotes synthetic cannabinoids currently banned in the
U.S.

The lack of adequate legal restrictions placed on many novel drugs of abuse with a high
abuse potential pose a unique set of challenges for substance abuse educators and law
enforcement agencies. For example, emerging substances are often legally available for a period
of time before laws are enacted that restrict the sale, distribution, and possession of them.
Additionally, laws designed to limit specific substances or compounds, once they are enacted,
can be rendered ineffective because manufacturers of many of these emerging substances replace
the banned substances with pharmacologically analogous compounds not currently under
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restriction. This latter predicament has been referred to in the literature as a “fruitless game of
‘whack-a-mole’” and, as a result, some governmental restrictions, both national and state-wide,
have included a general ban on entire classes of substances such that any new derivative that is
pharmacologically similar to the regulated substance is also automatically restricted (Couslon &
Caulkins, 2011). Such was the case with two emerging synthetic drugs of abuse: synthetic
cannabinoids (e.g., Spice, K2) and synthetic amphetamines (i.e., “bath salts”), both of which
were recently classified as controlled substances under the federal Synthetic Drug Abuse
Prevention Act of 2012. However, laws of this type are not universal and the sale, distribution,
and possession of other less sensationalized emerging substances are currently regulated by state
laws making potentially dangerous substances readily available for individuals residing in states
without specific restrictions. Moreover, despite current governmental regulations, both
nationally and state-wide, many emerging substances are available at various websites online
through sellers in the United States and abroad, making enforcement of laws that restrict the sale
of these banned substances problematic.
1.3

SYNTHETIC MARIJUANA
The use of synthetic marijuana has emerged as a serious public health threat in recent

years (National Institute on Drug Abuse, 2012). Emergency calls to poison control centers rose
dramatically after the initial introduction of synthetic marijuana and only recently have calls to
U.S. poison control centers begun to taper off. For example, in 2009, one year after U.S.
Customs and Border protection first encountered Spice and similar products (DEA, 2012), 13
calls were made to U.S. poison control centers across 41 states regarding the use of these
products. By 2011, the number of calls made to U.S. poison control centers reached 6,968 calls.
In 2012, however, the number dropped to 5,230 and, in 2013, it dropped even further to 2,657

6

(American Association of Poison Control Centers, 2014). Surprisingly, estimates suggest that the
sale of synthetic marijuana constitutes a multi-billion dollar industry annually in North America
alone (Paynter, 2011).
Results from the 2013 Monitoring the Future (MTF) survey revealed that 7.9% of high
school seniors reported using synthetic marijuana (e.g., Spice, K2) in the year preceding the
survey. In 2012, 11.3% of high school seniors reported past year use of synthetic marijuana. In
2011, the first year that the MTF survey assessed use of synthetic marijuana, 11.4% of high
school seniors reported use of synthetic marijuana in the past year. Anecdotal reports suggest
that individuals are using these products as “legal” alternatives to marijuana. Moreover, synthetic
marijuana products (e.g., Spice, K2) are commonly found online and at “head shops” throughout
the country. The majority of these products are sold as “incense” or natural “herbal blends” most
likely representing an attempt on the part of manufacturers to either deceive consumers or
circumvent governmental restrictions via misleading labeling practices (Zimmerman,
Winkelman, Pilhatsch, Nees, Spanagel, & Shulz 2009). In what may be an attempt to disguise
the active ingredients, synthetic marijuana often contains various “natural” ingredients (e.g.,
damiana) which, by themselves, are known to have psychoactive and euphoria-inducing effects.
However, it is the synthetic cannabinoids contained in these products which are primarily
responsible for their psychoactive effects. In fact, during the manufacturing process, synthetic
cannabinoids are sprayed onto any organic plant matter the manufacturer deems suitable and are
allowed to dry before packaging (DEA, 2012; Paynter, 2011). Moreover, many of the synthetic
cannabinoids, or cannabinomimetics, that have been identified in these “herbal blends” (e.g.,
JWH-018) are highly potent with some specific cannabinomimetics displaying a 20 fold greater
affinity for cannibinoid (e.g., CB1) receptor sites than that of traditional marijuana (Hudson,
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Ramsey, King, Timbers, Maynard, Dargan, et al., 2010; Psychonaut Web Mapping Research
Group, 2009). The greater affinity of these synthetic cannabinoids to CB1 receptor sites than that
of traditional tetrahydracannabinol (THC) translates to more pronounced intoxication.
The physiological effects which occur as a result of smoking these “herbal blends” can
include dangerous increases in blood pressure, delusions, and paranoia (Johnson, Johnson, &
Alfonzo, 2011; Zimmerman, et al., 2009). In addition, case reports have evidenced behavioral
and physiological phenomena (e.g., nausea, tremors, nightmares, unrest, sweating) that are
consistent with both DSM-IV and ICD-10 criteria for dependence and withdrawal, respectively
(Zimmerman et al., 2009).
1.4

SALVIA DIVINORUM
Salvia (also known as Diviner’s sage, magic mint) has also emerged as a drug of concern.

Historically, salvia has been used ritualistically by indigenous natives residing in highlands of
Southern Mexico for divination as well as for conditions such as headaches and bowel
irregularities (Valdes, Diaz, & Paul, 1983). However, the recent use of salvia among youth and
young adults appears to be largely recreational in nature. For example, in a recent study of 25
young adults (ages 18-29) who had used salvia in the year preceding the study, none reported
using salvia for entheogenic (religious or spiritual) purposes (Kelly, 2011).
Only recently have nationally representative surveys begun to track the use of salvia
among youth and young adults. Beginning in 2009, the Monitoring the Future survey included
questions assessing the use of salvia among high school seniors, college students, and young
adults. In 2010, questions assessing the use of salvia among 8th graders and 10th graders were
included in the survey. In 2012, for 8th graders, 10th graders, and 12th graders the annual
prevalence rates were 1.4%, 2.5%, and 4.4%, respectively. In 2012, among young adults
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between the modal ages 19-28, 1.1% reported past year use of salvia, a marked decrease from the
previous 2 years (2.5% in 2011 and 3.4% in 2010).
Currently, salvia is legal across much of the United States and typically can be found
online or at various “head shops” throughout the country. Moreover, salvia is available in
various concentrations which are manufactured to be 5, 10, and 20 times their natural strength
with higher concentrations delivering a (purportedly) more intense subjective “high.” Salvia is
typically smoked and the effects of salvia are relatively short, lasting from 5-20 minutes.
However brief the acute effects may be, users often report very intense, bizarre accounts of their
experiences. In fact, the very intensity of subjective experiences may actually be a deterrent for
future use. Anecdotal reports suggest that the sheer intensity of the drug experience has led some
first time users to report that they would never use the substance again (Kelly, 2011).
Salvia is unique among hallucinogens in that the active ingredient Salvinorin A does not
act on serotonergic receptors, like more traditional hallucinogens (e.g., LSD) but, rather, on
kappa-opioid receptors in the brain (National Institute on Drug Abuse, 2012). Some case reports
have evidenced paranoid symptomatology and cognitive impairment in individuals as a result of
using salvia (Prisinzano, 2005; Singh, 2007). However, more studies are needed to fully
elucidate the possible physiological and psychological harm that might arise as a result of both
short and long term use of salvia.
1.5

OVER-THE-COUNTER (OTC) MEDICATIONS CONTAINING
DEXTROMETHORPHAN
The recreational abuse of OTC medications containing dextromethorphan (e.g.,

Coricidin, Robitussin) has also emerged as a disturbing trend among high school students in
recent years. In 2006, questions assessing abuse of OTC medications containing DXM first
appeared in the MTF survey. Prevalence rates for abuse of OTC medications in the past year are
9

non-trivial. For example, among 8th graders, 10th graders, and 12th graders, 3.0%, 4.7%, and 5.6%
reported abusing OTC medications in the past year (Johnston et al., 2013). Questions addressing
annual or lifetime use of OTC medications in college students and young adults were not
included in the 2012 Monitoring the Future survey, nor in previous administrations of the survey
(Johnston et al., 2013).
Extrapolating from U.S. Census data, in 2009 an estimated 22,104,183 persons age 15 –
19 were living in the United States (U.S. Census Bureau, 2010). If only 5% of these young adults
have tried OTC medications containing DXM for the purposes of getting buzzed or high in the
past year, then this estimate would represent more than 1 million young people.
Dextromethorphan is an antitussive agent present in many cough and cold OTC
medications/preparations (Schwartz, 2005). Dextromethorphan’s antitussive (i.e. cough
suppressing) properties are believed to occur as a result of sigma opioid receptor activity
(Brown, Fezoui, Selig, Schwartz, & Ellis, 2004). Moreover, dextromethorphan and its metabolite
dextrorphan act on the phencyclidine receptor (PCP)-1 receptor and can produce PCP and
ketamine-like effects (e.g., dissociative symptoms such as depersonalization and derealization).
Reports of dextromethorphan intoxication have been described in the literature since the 1960s
(Logan, Yeakel, Goldfogel, Frost, Sandstrom, & Wickham, 2012). Symptoms of DXM
intoxication can be life-threatening and may include increased heart rate and blood pressure,
slurred speech, paranoia, confusion, hallucinations, and impaired motor function (Logan, et al.,
2012; National Institute on Drug Abuse, 2013). In addition, DXM intoxication has been
associated with aggressive behaviors including suicide, assault, and homicide (Logan et al.,
2012).
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In short, the recreational abuse of OTC medications containing dextromethorphan is of
great concern and is perhaps one of the more dangerous drug use trends in recent years given its
documented toxicity. Moreover, the abuse of OTC medication containing DXM is particularly
troubling given its widespread availability.
1.6

PREVALENCE RATES OF OTHER EMERGING DRUGS
Although recent years have witnessed increases in the use of emerging drugs such as

synthetic marijuana and salvia, little is known regarding the proportion of young adults using
other emerging drugs of abuse such as ecstasy-related substances (e.g., BZP) as well as kratom,
an herb with opiate-like properties. The use of “bath salts” containing synthetic cathinones was
recently included in the 2012 MTF survey for the first time. Past year prevalence rates for the use
of bath salts were low. Among 8th, 10th, and 12th graders 0.8%, 0.6%, and 1.3% reported past
year use of bath salts (Johnston et al., 2013).
1.7

PERCEIVED HARMFULNESS OF EMERGING DRUGS
Although the actual harmfulness of many emerging drugs are known, until recently, little

was known about the perceived harmfulness of many emerging recreational drugs including
synthetic marijuana, salvia, and “bath salts” containing substituted cathinones. For example, in
2012 questions assessing the perceived harmfulness of these latter substances were included in
the MTF survey for the first time among high school students. Approximately, 23.5% of 12th
graders indicated “great harm” for using synthetic marijuana once or twice and 32.7% indicated
“great harm” for using synthetic marijuana occasionally. In addition, 13.8% and 23.1% of 12th
graders indicated “great harm” for experimental and occasional use of salvia, respectively.
Moreover, 33.2% and 45.0% of high school seniors indicated “great harm” for experimental and
occasional use of bath salts (Johnston et al., 2013). Lastly, questions assessing the perceived
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harmfulness of abusing OTC medication were not included in the 2012 MTF survey nor in
previous years of the survey.
Assessing the perceived harmfulness of abusing OTC medication may be particularly
important because several studies have suggested that as perceived level of harm increases there
is a concomitant decrease in drug use. Bachman, Johnston, O’Malley, and Humphrey (1998)
examined the relationship between perceived risk of marijuana use and marijuana use trends over
a 30 year period using nationally representative data from the 1976-1996 MTF surveys. Notably,
in 1978, when perceived risk for using marijuana was at its lowest point, marijuana use rates
were at their highest (37% past 30 day prevalence among high school seniors). Conversely, in
1992, when perceived risk was at its highest point, marijuana use rates were at their lowest (12%
past 30 day prevalence among high school seniors). Although these data are correlational and,
hence, not indicative of causality, these trends suggest that social marketing strategies that
realistically present the risk for using emerging drugs may be a reasonable prevention strategy.
1.8

RISK PERCEPTION
Risk perception influences many decisions ranging from deciding whether to take a

prescription medication to deciding which motor vehicle is the safest option. Health care
providers communicate the risks of undergoing medical procedures. Public safety advertisements
communicate the risks of drinking and driving. Anti-drug ads communicate the risks associated
with using illicit drugs. Often, the goal of risk communication in social marketing campaigns is
to motivate individuals to decrease unhealthy behaviors (e.g., smoking) and increase healthy
behaviors (e.g., regular exercise). Perceptions of personal risk are thought to be central to one’s
motivation to engage in self-protective behavior. In fact perceptions of risk are a central
component of several models of health behavior change. For example in Protection Motivation
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Theory (PMT), risk perception is comprised of perceptions of vulnerability to a particular threat
or condition (e.g., likelihood of contracting an illness, likelihood of an experiencing an adverse
drug reaction) and perceptions about the severity of a particular condition (e.g., degree of harm
or disability). Perceptions of both vulnerability and severity influence one’s “threat appraisal”
(Rosenstock, 1974). It is one’s appraisal of a particular threat that contributes to one’s motivation
to take self-protective actions (e.g., wear sunscreen, quit smoking).
Similarly, in the Health Belief Model, perceptions of risk are influenced by the perceived
susceptibility to a particular threat or condition and the perceived seriousness of a particular
threat or condition (Rogers, 1975). The conceptualization of risk in PMT as vulnerability and
severity and in the HBM as susceptibility and seriousness underscore an important distinction in
the conceptualization of risk with one aspect of risk addressing vulnerability and susceptibility
and the other aspect of risk addressing severity and seriousness.
This dual concept of risk as a product of perceived vulnerability/perceived susceptibility
and perceived severity/perceived seriousness is reflected in studies assessing individuals’
perceptions of risk. In such studies individuals’ perceptions of vulnerability or susceptibility to a
particular threat or condition are assessed by having participants indicate the likelihood that they
would experience that outcome by assigning either a verbal (e.g., “slight chance”) or numerical
likelihood estimate (e.g., “20% chance”). Studies assessing the perceived severity or seriousness
of a particular condition often have participants indicate the perceived level of harm associated
with a particular condition using verbal descriptors (e.g., “very harmful”). Past research has
defined risk as the product of participants’ scores on likelihood estimates using verbal
descriptors (e.g., “slight chance”) and scores on an item assessing perceived level of harm (e.g.,
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“very harmful”; Bestch, Ulshofer, Renkewitz, & Bestch ,2011; Weinstein, Kwitel, McCaul,
Magnan, Gerrard, & Gibbons, 2007).
Regardless of how risk is operationalized in the literature, perceptions of risk are vital to
decision-making. Interestingly, research has demonstrated that one’s degree of sensation seeking
is associated with how one perceives risk (described below in Section 1.9).
1.9

SENSATION-SEEKING, RISK APPRAISAL, AND RISKY BEHAVIOR
Interestingly, an individual’s perception of risk is influenced, in part, by the degree to

which they have a propensity for being sensation-seeking. Sensation-seeking is defined as "[the]
need for varied, novel, and complex sensations and experiences and the willingness to take
physical and socialrisks for the sake of such experiences" (Zuckerman, 1979a). Many studies
have supported relationships between sensation seeking, risk taking and drug related behaviors.
For example, Rosenbloom (2003) found that sensation-seeking was negatively correlated with
risk evaluations and positively associated with risk-taking behavior in a sample of 75 university
students (Mage = 22.6, SD = 1.45). In addition, Penacoba, Gonzalez, Carretero, and Lopez (2008),
found that sensation seeking was associated with alcohol use. Moreover, Penacoba et al. (2008)
found that positive attitudes toward use of MDMA mediated the relationship between sensation
seeking and use of MDMA. Given the relationship between sensation-seeking, risk perceptions,
and risky behavior it is important that research that examines risky behaviors (e.g., drug use) and
risk perception include measures of sensation seeking.
1.10

ANALYTICAL VERSUS EXPERIENTIAL PROCESSING IN RISK
PERCEPTION
Historically, the majority of theories describing the evaluation of risk were

conceptualized as primarily analytical. These “rationalist” models typically assume that
individuals consciously weigh the risks and benefits of possible outcomes before arriving at a
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logical, reasoned, decision to engage or not engage in a particular behavior (Leiserowitz, 2006).
Recently, however, an appreciation of the role of affect in risk perception has emerged as a
contributing factor in the evaluation of risk.
The role of affect is elaborated in dual information processing models that describe the
processes by which one evaluates risk (Chaiken & Trope, 1999; Sloman, 1996;). These distinct
processing “routes” are referred to as the experiential system or System 1 and the analytic system
or System 2. The experiential system is characterized as reflexive, affect-oriented, and instinctual
whereas the analytic system is characterized as more logical, reason-oriented and deliberate. In
summary, the experiential system utilizes intuition and more gut-based emotionally-laden
visceral reactions to stimuli whereas the analytic system utilizes logic, reason, and statistical
thought in the assessment of risk or danger (Slovic et al., 2005).
Researchers such as Fischoff, Slovic, and Zajonc were among the first to demonstrate the
importance of affect in decision making. For example, studies conducted by Fischoff and Slovic,
beginning in the 1970’s, demonstrated that affective reactions such as dread influenced public
perceptions of risk and acceptance of those risks for a variety of hazards (Fischoff, Slovic,
Lictenstein, Read, & Combs, 1978; Slovic, 1987). Zajonc (1980) posited that emotionally-laden
reactions to stimuli often occurred spontaneously, subsequently influencing information
processing and decision making. In this way, emotional reactions to stimuli serve as priming
mechanisms, mechanisms which help one rapidly and efficiently react to a range of potentially
threatening situations.
1.11

INDIVIDUAL DIFFERENCES IN THE UTILIZATION OF EXPERIENTIAL
AND ANALTYIC SYSTEMS
Numerical ability (i.e., numeracy) has been shown to influence whether an individual is

more likely to rely on the experiential system or the analytical system to inform decisions. For
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example, Peters (2008) observed that individuals who have limited numeracy skills tend to rely
on non-numeric sources of information to inform decisions, whereas numerate individuals tend
to utilize numerical information when making decisions.
Dieckmann, Slovic, and Peters (2009) examined how individuals with varying degrees of
numeracy skills evaluated the likelihood of a hypothetical terrorist attack in two experiments. In
the first experiment Dieckmann et al. (2009) examined how individuals with varying degrees of
numerical ability use likelihood information when this information is presented with narrative
evidence or presented without narrative evidence. The experiment was run as a between-subjects
design in which there were 3 levels of uncertainty information, 2 levels of stated likelihood
information, and 2 levels of narrative evidence. The 3 levels of the uncertainty information were:
(1) a verbal format condition in which participants read verbal descriptors of likelihood (e.g.,
highly unlikely, fairly unlikely), (2) a frequency format condition in which participants read
likelihood estimates presented as frequencies (e.g., 5 out of 100, 20 out of 100), and (3) a
percentage format condition in which participants read likelihood estimates presented in
percentages (5%, 20%). In addition, the stated likelihood of attack was varied at two levels (5%
vs. 20%). Lastly, narrative evidence (e.g., “Yesterday afternoon a foreign newspaper printed a
statement from the militant group XXX warning of an attack on the U.S.”) was varied at two
levels (no narrative evidence and narrative evidence).
Participants read one “intelligence report” about a potential terrorist attack in
Washington, D.C. Intelligence reports contained statistical information about the likelihood of an
attack as well as a statement about the potential devastation that would ensue if the attack
occurred (e.g., potential lives lost, amount of property damage). Some participants read
intelligence reports that contained narrative evidence (e.g., “Yesterday afternoon a foreign
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newspaper printed a statement from the militant group XXX warning of an attack on the U.S.”)
while other participants read intelligence reports that did not contain narrative evidence. After
reading these intelligence reports participants then rated the likelihood of the (hypothetical)
terrorist attack occurring. Specifically, participants were asked to “‘rate the risk associated with
this possible attack.’” Participants could respond 0 indicating “very low risk” to 10 indicating
“very high risk.”
Among participants in the no narrative evidence condition, likelihood format (i.e., verbal,
frequency, percentage) did not significantly affect perceptions of risk. Moreover, among
participants in this no narrative evidence condition, perceptions of risk were higher when
information about stated likelihood was higher (e.g., 20%, 20 out of 100) than when stated
likelihood information was lower (e.g., 5%, 5 out of 100). In addition, participants lower in
numeracy reported significantly higher perceptions of risk than participants higher in numeracy
(less numerate M(SD) = 4.95(2.04); more numerate M(SD) = 4.28(2.30)). Contrary to the
authors’ expectations more numerate individuals, rather than less numerate individuals,
displayed greater variability in risk ratings when compared to less numerate individuals.
Among participants in the narrative evidence condition, likelihood format (i.e., verbal,
frequency, percentage) also did not significantly affect perceptions of risk. However, among
participants in the narrative evidence condition (unlike those in the no narrative evidence
condition), there was no difference in risk perceptions when stated likelihood information was
higher (e.g., 20%, 20 out of 100) than when state likelihood information was lower (e.g., 5%, 5
out of 100). This latter finding suggests that narrative information may cause individuals to
ignore base-rate (i.e. statistical) information when presented alongside narrative evidence. This
finding is consistent with the phenomena of base-rate neglect. Lastly, participants who displayed
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lower numeracy reported significantly higher perceptions of risk than participants higher in
numeracy (less numerate M(SD) = 5.43(2.46); more numerate M(SD) = 4.75(2.38)).
Unfortunately, results focused exclusively on the effect of information type (e.g., verbal,
frequency, percentage format) and stated likelihood of attack (5% vs 20%) on risk perceptions
separately for participants assigned to the no narrative evidence condition and participants
assigned to the narrative evidence condition. In short, main effects analyses (i.e., direct
comparisons) between participants assigned to the no narrative evidence condition and
participants assigned to the narrative evidence condition were not conducted, precluding an
assessment of the potential impact of narrative evidence on risk perceptions. Such a comparison
would have been particularly beneficial because little research (discussed later) has examined the
impact that narrative information has on risk perceptions when presented alongside statistical
information highlighting those risks.
In experiment two, Dieckmann et al. (2009) examined whether participants who
displayed low numeracy focused more on narrative evidence than participants who displayed
higher levels of numeracy. The experiment was similar to Study 1 (described above) but the
experiment was conducted as a mixed design with 2 levels of likelihood format as the between
subjects factor and 4 levels of likelihood as the within subjects factor. The two levels of
likelihood format were presented as (1) a probability statement (e.g., “The probability that this
event will occur is x%”) or a (2) “confidence” statement (e.g., “We are x% sure that this event
will occur”). The four levels of likelihood were: no stated likelihood, 1%, 5%, and 10%
(presented as percentages).
The authors used a multi-level mixed model approach with the within-subject factors
represented at level 1 (i.e., perceived likelihood level, ratings of coherence and credibility) and
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the between subjects factor represented at level 2 (i.e., likelihood format and numerical ability).
Participants rated the likelihood of an attack as significantly greater when the stated likelihood
increased. For each increase in stated likelihood (1%, 5%, 10%) there was a 2.38 unit increase in
perceived likelihood ratings on a 0-100% scale (p = .05). In addition, participants who rated the
information in the intelligence reports as higher in credibility and coherence perceived the attack
to be significantly more likely, on a scale from 0-100%, than those who rated the reports as
lower in credibility and coherence. Specifically, for each unit increase in perceived coherence
and credibility, there was a 3.19 unit increase in perceived likelihood ratings (p < .001).
In addition, less numerate individuals reported higher levels of perceived likelihood when
compared to more numerate individuals. Specifically, for each unit decrease in numerical ability
there was a 2.92 unit increase in perceived likelihood ratings (p = .05). Moreover, the association
between likelihood estimates and the perceived credibility of the message and likelihood
estimates and message coherence was greater among less numerate individuals when compared
to more numerate individuals. This pattern of results suggests, as the author’s point out, that
decision makers with limited numeracy skills are influenced to a greater extent by narrative
evidence and less so to explicitly stated likelihood information.
1.12

THE REPRESENTATIVENESS HEURISTIC, THE AVAILABILITY
HEURISTIC, AND BASE RATE NEGLECT
Several studies have suggested that individuals ignore base-rate information. For

example, the following has been said about base-rate neglect: “…it has repeatedly been shown
that people…ignore base-rate frequencies and, instead, base their judgments solely on the
similarity between the individual’s personality and the prototypes of the categories under
consideration” (Ginossar & Trope, 1987); “information about base-rates is generally observed to
be ignored” (Evans & Bradshaw, 1986); and “…psychological research suggests that people in
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general, including trained statisticians, ignore base-rate probabilities” (Christensen-Szalanski &
Bushyhead, 1981). More recently, however, the claim that people generally ignore based rates
has been called into question. For example Koehler (1996) states the following,, “…[n]ot only is
there little evidence that base-rates are routinely ignored but a critical review of the…literature
shows that base-rates usually influence judgments and often to so in reasonable ways” (Koehler,
1996).
Several explanations for the phenomena of base-rate neglect have been described in the
literature. One explanation is referred to as the representativeness heuristic. The
representativeness heuristic is the tendency to estimate the probability that a target belongs to a
certain category based on the degree to which that target fits the stereotype of that category. For
example, in the famous lawyer-engineer problem, Tversky and Kahneman (1974) provided
participants with 100 personality descriptions. Participants were told that 30 of these descriptions
were about engineers and 70 of these descriptions were about lawyers. Subjects then read 5
“random” personality descriptions from the list of 100 personality descriptions and were asked to
determine the probability that the person described was an engineer or a lawyer. Notably,
participants based probability estimates that the given description depicted an engineer (rather
than a lawyer) based on the degree to which the personality description fit the stereotype of an
engineer and not on the given base-rate information.
A second explanation described in the literature that explains the phenomena of base-rate
neglect is referred to as the availability heuristic. This availability heuristic is the tendency to
base subjective probability estimates on how easily instances are retrieved from memory
(Tversky & Kahneman, 1974). In other words, the availability heuristic is an individuals’
tendency to confuse the ease with which something comes to mind with the frequency that it
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occurs. For example, imagine the likelihood that you might be involved in a plane crash
sometime in the next year. Now imagine that you recently heard a news report detailing the
circumstances surrounding a recent, highly televised plane crash. After being exposed to this
news coverage, what is your estimate of the likelihood of being involved in a plane crash?
Chances are your estimates of being involved in a plane crash are higher after being exposed to
such information.
1.13

STATISTICAL VERSUS NARRATIVE EVIDENCE IN RISK PERCEPTION
Several studies have investigated whether statistical evidence is more persuasive than

narrative evidence when communicating risk. Some studies suggest that statistical evidence is
more persuasive, while others suggest that narrative evidence is more persuasive. However, the
majority of these studies have utilized between-subjects designs in which one group of subjects
is given narrative information and the other group of subjects is given statistical information
about the risk of engaging in a particular behavior. After exposure to either statistical or narrative
evidence, participants then rate (1) the likelihood of experiencing an adverse outcome and (2) the
severity of that outcome.
Importantly, because these studies have examined the persuasiveness of statistical and
narrative evidence using between-subjects designs no conclusions can be drawn regarding the
relative impact of anecdotal and statistical evidence on risk evaluations. Notably, in the context
of the real world individuals are unlikely to be exposed solely to statistical or narrative risk
information. Indeed, it is more likely that individuals will have to reconcile statistical evidence
with contradictory narrative reports. Studies investigating how individuals weigh such
conflicting evidence are lacking. In fact, few published papers have directly examined the impact
of anecdotal evidence on decision-making when this information is presented in conjunction with
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statistical information. The present study extends the above research in the context of “novel”
drug use. More specifically, the present study investigates the extent to which the presence of
anecdotal information decreases reliance on statistical information when young adults evaluate
the risks associated with the use of novel, emerging drugs.
The next section reviews between-subject studies that compare the persuasiveness of
statistical and narrative evidence.
1.14

THE PERSUASIVENESS OF STATISTICAL VERSUS NARRATIVE EVIDENCE
Between-subjects designs have yielded inconsistent evidence regarding the

persuasiveness of anecdotal and statistical evidence. A meta-analysis of 15 studies found that, on
average, statistical evidence was more persuasive than narrative evidence (d = .20; Allen &
Preiss, 1997). Studies included in this meta-analysis examined a range of outcomes related to
persuasion including consumer decision-making, teachers’ evaluations of elementary science
programs, and evaluations of alcohol education messages.
In a recent review, Hornikx (2005) examined the persuasiveness of different evidence
types across 14 studies. Eleven of the studies focused exclusively on a comparison between
statistical versus narrative evidence when these evidence types were presented in betweensubjects designs. Notably, 6 of the 11 studies reported an advantage for statistical evidence over
narrative evidence, and the remaining 5 studies reported no advantage for one evidence type over
the other. The results of these studies are summarized below (see Table 2 below).
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Table 2: Results of investigations examining persuasiveness of statistical and anecdotal evidence
(adapted)
Investigators
Slater et al. (1996)
n = 218

Type of Design
Between-Subjects

Outcome Variable
Agreement with the claim that
use of alcohol is harmful to
society

Result
Statistical evidence
more persuasive

Hoeken et al. (2003)
n= 160

Between-Subjects

Agreement with twenty general
claims

Statistical evidence
more persuasive

Allen et al. (2000)
n= 1270

Between-Subjects

Agreement with fifteen general
claims

Statistical evidence
more persuasive

Baesler et al. (1994)
n = 292

Between-Subjects

Statistical evidence
more persuasive

Dickson (1982)
n = 174

Between-Subjects

Agreement with the claim that
majority of juvenile delinquents
do not become adult criminals
Evaluation of the breakdown
rate of a household appliance

Hoeken (2001a)
n = 324

Between-Subjects

Cox et al. (2001)
n = 174

Between-Subjects

Baesler (1997)
n = 295

Between-Subjects

Hoeken (2001b)
NA

Between-Subjects

Kazoleas (1993)
n = 176

Between-Subjects

Sherer et al. (1984)
n = 80

Between-Subjects

Evaluation of the Likelihood
that a new cultural center will
be successful
Evaluation of the benefits of
regular screening for breast
cancer
Agreement with claims
involving crime and birth
control
Agreement with claim that
taxes should be raised to
reduce burglaries by increasing
number of streetlights on streets
Agreement with a claim about
the effectiveness of using a
seatbelt

Agreement with a claim stating
that reducing one’s use of
alcohol decreases the chance of
experiencing undesirable
consequences
Note: adapted from Hornikx (2005); NA= not available

Statistical evidence
more persuasive
Statistical evidence
more persuasive
Equivocal

Equivocal

Equivocal

Equivocal

Equivocal

Greene and Brinn (2003) examined the impact of statistical and narrative information on
tanning behavior in college women. Participants (n =141) were exposed to one of three message
conditions: (1) a statistical format condition in which participants read base-rate information
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highlighting the risks associated with tanning and the use of tanning beds, (2) a narrative format
condition in which participants read a narrative about a young woman who used tanning beds
and later developed skin cancer, and (3) a control condition in which participants read neither
statistical or narrative evidence. Use of tanning beds was assessed at pretest using the following
question, “How many times have you used a tanning bed in the past month?” At post-test, one
month later, participants were asked, “’Would you please estimate how many times you have
used a tanning bed in the past month?’” For the main outcome, tanning at post-test was
subtracted from reported tanning behavior at pretest yielding a difference score where a positive
score would indicate a reduction in tanning bed use.
Participants assigned to the statistical evidence condition significantly decreased tanning
behavior one month later compared to participants who were assigned to the control condition
(M(SD) = -0.85(2.97) versus M(SD) = -3.22(6.16)). Tanning behavior did not differ between the
narrative evidence condition and the control condition or between the statistical evidence
condition and the narrative evidence condition.
Participants assigned to the statistical evidence condition and the narrative evidence
condition did not differ in their intentions to use tanning beds. However, both the statistical
evidence condition (M(SD) = 2.67(1.42)) and narrative evidence condition (M(SD) = 2.73(1.59))
reported significantly lower ratings on intention to use tanning beds compared to the no evidence
control condition (M(SD) = 3.10(1.44). Intention to tan was assessed using 3 items (e.g., I am
likely to use a tanning bed in the next month). Five response options ranged from “strongly
disagree to “strongly agree.” Items assessing intentions to tan were summed and averaged for
analysis where higher scores indicated greater intentions to tan.
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De Wit, Das, and Vat (2008) examined the impact of statistical and anecdotal information
on perceptions of risk and intentions to get a Hepatitis B vaccine among men who have sex with
men (MSM), a group at risk for contracting hepatitis B. One hundred eighteen participants were
assigned to one of four conditions: (1) a narrative evidence condition in which participants read
general risk information about hepatitis B and a first-person anecdote from an individual who
contracted hepatitis B, (2) a statistical evidence condition in which participants read general risk
information about hepatitis B and epidemiological information (i.e., base-rate information) about
the prevalence of hepatitis B among MSM, (3) a mere assertion of increased risk condition in
which participants read general risk information about hepatitis B, and (4) a control condition
that included information about the consequences of contracting hepatitis B. Risk was assessed
using three items (e.g., “The likelihood of becoming infected with HBV because of my sexual
behavior is substantial”). Seven response options ranged from “totally disagree” to “totally
agree.” Intentions to receive a HBV vaccination was assessed using three items (e.g., “Are you
planning on getting vaccinated for hepatitis B in the future?”). Seven response options ranged
from “certainly not” to “certainly.”
Participants who were randomly assigned to the narrative evidence condition rated the
risk of hepatitis B as significantly higher than participants who were assigned to the mere
assertion of increased risk condition (M(SD) =3.45(0.30) vs. 2.23(0.27), respectively). Risk
evaluations were not significantly different between participants who were randomly assigned to
the statistical evidence condition and participants who were assigned to the mere assertion of
increased risk condition (M(SD) = 2.89(0.29) vs. 2.23(0.27), respectively). In addition, no
significant differences were found in risk evaluations between participants assigned to the
narrative evidence condition and the statistical evidence condition (M(SD) = 3.45(0.30) vs.
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2.89(0.29), respectively). Similarly, no significant differences were found in intentions to get a
hepatitis B vaccine between participants assigned to the narrative evidence condition and the
statistical evidence condition (M(SD) = 5.31(0.41) vs. 4.40(0.40), respectively).
Importantly because participants were randomly assigned to condition (narrative
evidence, statistical evidence, mere assertion of increased risk, and a control condition) no
conclusions can be drawn regarding how the presence of narrative (i.e. anecdotal) evidence may
have influenced variables related to decision making when individuals are also presented with
statistical information highlighting those risks.
In summary, the studies reviewed in this section investigated the effect of statistical or
narrative information on risk perception and intentions when these evidence types are presented
separately. The next section reviews how individuals weigh the relative impact of statistical and
narrative evidence when these evidence types are presented in combination.
1.15

THE RELATIVE IMPACT OF STATISTICAL AND NARRATIVE EVIDENCE
Few published papers have examined the relative impact of statistical (base-rate)

evidence and narrative evidence on decision making when these evidence types are presented in
combination. Ubel, Jepson, and Baron (2001) conducted two studies examining how patients
with angina made a hypothetical decision to undergo either angioplasty or bypass surgery.
In the first study, all participants were given statistical information regarding the
percentage of individuals who benefited from undergoing angioplasty and bypass surgery (50%
and 75%, respectively). In addition, all participants read narrative evidence in the form of
testimonials from two patients who had undergone an angioplasty; one in which the patient
benefited from angioplasty and one in which the patient did not benefit from angioplasty.
Participants also read testimonials of patients who underwent bypass surgery. One-half of the
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participants were assigned to a “proportionate group” in which they read a proportionately
equivalent number of testimonials about bypass surgery as indicated by the base rate
information. Specifically, the proportionate group read 4 testimonials from patients who had
bypass surgery; 3 in which the patients benefited from bypass surgery and 1 in which the patient
did not. The other half of the participants were assigned to a “disproportionate” group in which
they read 2 testimonials about bypass surgery; 1 in which the patient benefited from bypass
surgery and 1 in which the patient did not.
Notably, participants assigned to the proportionate group “chose” bypass surgery 44% of
the time and participants in the disproportionate group “chose” bypass surgery 30% of the time.
This pattern of results suggests that the mere presence of contradictory narrative evidence may
lead to the underutilization of statistical information in the decision to undergo bypass surgery,
an outcome consistent with the phenomena of base-rate neglect. For example, if participants had
been purely analytical in the evaluation of risk then participants assigned to the proportional
group as well as the disproportionate group should have chosen bypass surgery 100% of the time
because it was clearly the more efficacious treatment option (bypass surgery success rate = 75%;
angioplasty success rate = 50%). Participants assigned to the proportional group “chose” bypass
surgery 44% of the time, whereas those assigned to the disproportionate group chose bypass
surgery 30% of the time (see Table 3 below). Based on this pattern of results the authors
conclude that efforts to present testimonials that are proportionately equivalent to the stated
statistical probabilities (regarding those who benefit from a particular treatment) cannot always
be assumed to be the ideal strategy.
Another way to frame the findings is that the mere presence of counter-evidence in the
form of narratives (e.g., testimonials of patients who did not benefit from bypass surgery) may be
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sufficient to reduce one’s reliance on statistical information when evaluating treatment options.
This may help explain the findings of the current study. For example, in the proportional group
the presence of counter-evidence was 1 in 4 or 25% of the testimonials read (in which 1 patient
did not benefit from bypass surgery and the remaining 3 did). In the disproportionate group, the
presence of counter evidence was 1 in 2 or 50% of the testimonials read. If patients are adjusting
the benefits of bypass surgery as a function of the proportion of narrative counter-evidence they
are exposed to, this may explain the finding that participants in the disproportionate group
minimized the benefits of bypass surgery to a greater extent than those in the proportionate group
(30% vs. 44% chose bypass surgery).
Table 3: Percent Choosing Bypass Surgery

Base-Rate Only

Base-Rate Plus
Proportionate
Testimonials

Base-Rate Plus
Disproportionate
Testimonials

Study 1

---

44%

30%

Study 2

58%

37%

34%

Note: Findings from Ubel et al. (2001).
Findings from the Study 2 support the above interpretation. Study 2 was identical to
Study 1 with the following exceptions. First, in Study 2 participants were randomly assigned to
an additional no narrative evidence control condition in which patients just received base rate
information about the percentage of patients who benefit from angioplasty and bypass surgery
(50% and 75%, respectively). This was done so that the percentage of patients choosing bypass
surgery in the absence of narrative evidence could be explored. Second, participants in study 2
read the same base rate information about those who benefit from angioplasty and bypass
surgery (50% and 75%, respectively) as in Study 1. However, participants in Study 2 read a total
of 4 testimonials from patients who had undergone angioplasty; two of these testimonials were
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from two patients who did benefit from angioplasty and the other two testimonials were from
patients who did not benefit from angioplasty. This is in contrast to Study 1 in which participants
read a total of 2 testimonials from patients who had undergone angioplasty. In study 1, one of
these testimonials was from a patient who benefited from angioplasty and the other testimonial
was from a patient who did not benefit from angioplasty.
Lastly, participants in Study 2 who were randomly assigned to the disproportionate
group received 4 testimonials of patients who had bypass surgery: 2 in which the patients
benefited from bypass surgery and 2 in which the patient did not. This is in contrast to Study 1 in
which participants assigned to the disproportionate group read 2 testimonials about bypass
surgery; one in which the patient benefited from bypass surgery and one in which the patient did
not benefit from bypass surgery.
Participants assigned to no narrative control condition in Study 2 chose bypass surgery
58% of the time, whereas participants assigned to the proportionate group and the
disproportionate group chose bypass surgery 37% and 34% of the time, respectively. This
pattern of results suggests that the mere presence of anecdotes (e.g., testimonials) may influence
individuals to rely less on base-rate information when evaluating treatment options. Importantly,
this paper is one of few publications that examined the impact of anecdotes on decision-making
when these anecdotes are presented in combination with statistical (base-rate) information.
Another paper examining the relative impact of statistical and narrative evidence in the
evaluation of risk was conducted by Bestch et al. (2011). Specifically, Betsch et al. (2011)
conducted two studies investigating how exposure to anecdotal reports that describe adverse
vaccination reactions in children influences perceived vaccination risks when these anecdotal
reports are presented alongside statistical information highlighting the percentage of children
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who experience adverse vaccination reactions. Study 1 investigated the degree to which
systematically varying the number of narratives reporting adverse reactions to a vaccination
influenced perception of risk and vaccination intentions when this information was presented in
combination with statistical (base rate) information highlighting those risks. Study 2 investigated
whether anecdotes that varied in emotionality and richness influences perceived vaccination
risks.
Study 1 included 72 undergraduates from Germany (23.7% male; Mage =22 years).
Participants were asked to imagine that they placed an inquiry about experiences with a
particular childhood vaccination on an online bulletin board. Participants then read a set of
hypothetical responses to their inquiry. The first response cited a recent study by the World
Health Organization reporting the incidence of adverse reactions following the target vaccination
(e.g., 20 adverse reactions out of 100). The subsequent 10 postings contained responses in the
form of first hand anecdotes, with some anecdotes reporting adverse reactions in children to a
vaccination, with others reporting no adverse reactions. The narratives were taken from real
websites in which parents posted vaccination reactions in their children.
Participants were randomly assigned to one of four conditions: (1) a statistics only
condition in which participants read only base-rate information about the percentage of children
who experience an adverse vaccination reaction (e.g., 20 out of 100 experience an adverse
reaction) , (2) a statistics plus anecdotal evidence condition in which participants read the same
base rate information plus an additional 10 anecdotes, 1 of which described an adverse
vaccination reaction, (3) a statistics plus anecdotal evidence condition in which participants read
the same base rate information plus an additional 10 anecdotes, 2 of which described an adverse
vaccination reaction, and (4) a statistics plus anecdotal evidence condition in which participants
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read the same base rate information plus an additional 10 anecdotes, 4 of which described an
adverse vaccination reaction.
The main dependent measures were perceived probability of one’s child having an
adverse vaccination reaction, perceived severity of an adverse vaccination reaction, and
intentions to vaccinate their child in the future. Perceived probability was assessed using the
following question, “The probability of side effects following a vaccination against [illness]]
are?” Seven response options ranged from “no chance” (1) to “certain” (7). Perceived severity
was assessed using the following question, “How severe do you think the side effects of a
vaccination against the illness are?” Seven response options ranged from “not at all” (1) to
“extremely” (7). Risk perception was calculated as the product of perceived probability and
perceived severity (possible range of scores: 1-49). Vaccination intentions were assessed using
the following question: “If you had the possibility to vaccinate your child during the next week,
what would you do?” Seven response options ranged from “definitely not vaccinate” (1) to
“definitely vaccinate” (7).
Risk perception ratings increased as the number of anecdotes describing adverse
vaccination reactions increased. Analyses were restricted to the examination of differences
between the conditions that included anecdotal reports. Risk perception ratings for the groups
were as follows: (1) statistics only condition = 15.15 (SD = 10.67), (2) statistics plus 1 adverse
vaccination reaction condition = 11.25 (SD = 7.47), (3) statistics plus 2 adverse vaccination
reactions condition = 13.21 (SD = 7.91), and (4) statistics plus 4 adverse vaccination reactions
condition = 18.74 (SD = 10.47). A marginally significant difference was found between groups
2 and 3 and groups 3 and 4 (p’s = .055 and .054, respectively).
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Intentions to vaccinate decreased as the number of anecdotes describing adverse
vaccination reactions increased. Intentions to vaccinate among the groups were as follows: (1)
statistics only condition = 4.74 (SD = 1.24), (2) statistics plus 1 adverse vaccination reaction
condition = 5.00 (SD = 1.45), (3) statistics plus 2 adverse vaccination reactions condition = 4.74
(SD = 1.52) and (4) statistics plus 4 adverse vaccination reactions condition = 3.42 (SD = 1.68).
Analyses were restricted to the examination of differences between the conditions that included
anecdotal reports (groups 2, 3, and 4). A univariate ANOVA (with 1, 2, and 4 adverse
vaccination reaction conditions as the between-subjects factor) revealed that with an increasing
number of adverse narratives, intentions to vaccinate decreased significantly (F (2, 58) = 5.729, p
< .01, eta 2 = .17).
Study 2 included 313 undergraduates from Germany (12.9% female; Mage = 20.47 years).
As in Study 1, participants were asked to imagine that they placed an inquiry about experiences
with a particular childhood vaccination on an online bulletin board. Participants then read a set of
hypothetical responses to their inquiry. However, Study 2 was designed to examine whether
changes in the emotionality of the narrative and richness of the narrative were associated with
changes in perceived vaccination risk and intentions to vaccinate. To examine the potential
impact of emotionality and richness Study 2 utilized a 2x2x2x2 between subjects design with the
following factors: emotionality of the narrative (high vs. low), richness of the narrative (high vs.
low), frequency of narratives reporting adverse vaccination reactions (2 vs. 4 narratives reporting
adverse reactions), and base-rate information about the percentage of children who experience an
adverse vaccination reaction (20% vs. 40% of children vaccinated experience an adverse
reaction).
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Significant main effects were found for the following factors: emotionality of the
narrative (high vs. low), frequency of narratives reporting adverse vaccination reactions (2 vs. 4
narratives reporting adverse reactions), and base-rate information about the percentage of
children who experience an adverse vaccination reaction (20% vs. 40% of children vaccinated
experience an adverse reaction). Narratives with high emotionality were rated as conveying
greater risk than narratives with low emotionality (17.52 vs. 15.33, respectively). In addition,
reading 4 out of 10 narratives reporting adverse vaccination reactions elicited higher risk ratings
than reading 2 out of 10 narratives reporting adverse reactions (18.77 vs. 14.32, respectively).
Lastly, base-rate information depicting a higher likelihood of an adverse reaction (i.e., 40%
likelihood of an adverse reaction) elicited higher risk ratings than base-rate information depicting
a lower likelihood of an adverse reaction (i.e., 20% likelihood of an adverse reaction; 18.22 vs.
14.85, respectively).
In summary, the studies reviewed in this section summarize the relative impact of
statistical and narrative evidence on decision-making, risk perceptions, intentions when these
evidence types are presented in combination. Moreover, these studies have examined the relative
impact of statistical and narrative evidence in the context of medical decision making (e.g.,
deciding to undergo a medical procedure and choosing a vaccination for one’s child(ren)). No
studies have examined how young adults weigh the relative impact of statistical and narrative
evidence when evaluating the risk of using an emerging drug of abuse. As such, research that
addresses this gap would represent an important contribution to the literature. Moreover, studies
that address this current gap in knowledge should have implications for improving health
communications designed to prevent or reduce the use of emerging drugs in young adults.

33

1.16

THE PRESENT STUDY
The current study seeks to fill in a critical gap in knowledge regarding how individuals

weigh the relative importance of statistical and narrative evidence when evaluating the risk of
using emerging drugs of abuse. Understanding how individuals use such information should
have important implications for communication strategies designed to prevent or reduce the use
of these substances.
1.17 HYPOTHESES
(1)

Exposure to anecdotal evidence that contradicts base-rate information will
minimize the perceived likelihood of harm associated with novel drug use

(2)

Exposure to anecdotal evidence that is consistent with base-rate information will
magnify the perceived likelihood of harm associated with novel drug use

(3)

Numerical ability will be associated with individuals’ perceived likelihood of
harm of using novel drugs
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Chapter 2: Methods
2.1

PARTICIPANTS
Four hundred fifty three undergraduate students (59% female; Mage = 19.60, SD = 2.15)

participated in this study. Hispanics comprised 84.3% of the sample. The breakdown of the
remaining ethnicities/racial backgrounds is as follows: Whites (6.0%), African Americans
(2.2%), and Asian Americans (1.8%). Two percent (2.7%) of the sample reported “Other” and
2.4% of the sample reported more than one ethnic/racial background. Fifty-one percent (51.2%)
of the sample were Freshmen, 26.2% were Sophomores, 16.9% were Juniors, and 5.1% were
Seniors. Seventy-four percent (74.3%) of the sample grew up in El Paso, TX followed by
Juarez, Mexico (11.1%), and Las Cruces, NM (0.2%). Additionally, 0.7% of the sample reported
growing up in El Paso and Juarez. Students were recruited from Introductory Psychology classes
and received one hour of research credit for their participation.
In conducting the power analyses (described below), several strategies were used to
estimate the effect size. First, the estimated population effect size was derived from 3 studies
most similar in design. Two studies conducted by Ubel et al. (2001), and one study, conducted
by Betsch et al. (2011), yielded the following effect sizes: d= .28, d= .40, and d= .33. The
average of these latter effect sizes yielded a small-to-medium effect size (d= .33). A weighted
average of these effect sizes, taking sample size into account, also yields a small-to-medium
effect size (d= .34). Using Jacob Cohen’s heuristics, a d of this magnitude lies between a small
effect (d= .2) and a medium effect (d= .5). Because the sample size required to detect a small
effect (d= .10) at 80% power would require a prohibitively large sample size (N = 726) and past
research suggests a small-to-medium effect size, a d of .34 (equivalent to f = .17) was chosen for
the power analysis described below.
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Using G*Power version 3.1.2 for each of the ANOVAs (described in the Approach to
Primary Analyses section) on the latter dependent measures, the sample size required to detect a
small to medium size effect (f = .17) at 80% power was 339 participants (Faul, 2009).
2.2

MEASURES
Background Survey I. A 7-item measure assessed basic demographic information

including age, gender, ethnic/cultural background, college level, grade point average, and selfreported language proficiency (see Appendix A).
Background Survey II. A 39-item self-report measure assessed lifetime use, past year
use, and past 30-day use of alcohol, cigarettes, cocaine, hallucinogens, heroin, hookah tobacco,
kratom, marijuana, methamphetamine, methaqualone, OTC cough and cold medication, salvia,
and synthetic marijuana. Items were adapted from the 2010 MTF survey. Items were presented
using the following format: “On how many occasions have you used [substance]…in your
lifetime…during the last 12 months…during the last 30 days?” Eight response options were
provided: (1) “Never,” (2) “1-2,” (3) “3-5,” (4) “6-9,” (5) “10-19,” (6) “20-29,” (7) “30-39,”
and (8)” 40 or more.”
In addition, 26 items assessed past subjective experiences with the following substances:
alcohol, tobacco, cocaine, hallucinogens, heroin, hookah tobacco, kratom, marijuana,
methamphetamine, methaqualone, (abuse of) OTC medications, salvia, and synthetic marijuana.
Specifically, participants responded to the following item: “Please indicate your experiences
with the following substances by placing a checkmark next to the appropriate space.” Response
options included: (1) “never tried,” (2) “tried and never had a bad experience,” (3) “tried and
sometimes had a bad experience,” and (4) “tried and often had a bad experience.” Similarly,
participants responded to the following item in order to assess past good experiences: “Please
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indicate your experiences with the following substances by placing a checkmark next to the
appropriate space.” Response options included: (1) “never tried,” (2) “tried and never had a
good experience,” (3) “tried and sometimes had a good experience,” and (4) “tried and often
had a good experience” (See Appendix B).
Drug Familiarity. A single item assessed familiarity with the following substances:
alcohol, tobacco, cocaine, hallucinogens, heroin, hookah tobacco, kratom, marijuana,
methamphetamine, methaqualone, salvia, synthetic marijuana, and abuse of OTC medication for
the purposes of getting buzzed or high. The survey item read as follows: “Before taking part in
this study had you heard of any of the following substances?” Response options included “yes”
and “no” (See Appendix C).
Perceived Harmfulness. A 12-item self-report measure assessed the perceived harm of
using alcohol, cigarettes, cocaine, hallucinogens, heroin, hookah tobacco, kratom, marijuana,
methamphetamine, OTC cough and cold medication, salvia, and synthetic marijuana. Perceived
harm was assessed for three levels of use: experimental use, occasional use, and regular use. Item
wording was adapted from the 2010 MTF survey. The following format was used to assess
perceived harm: “How much do you think people risk harming themselves (physically or in other
ways), if they…try [substance] once or twice…occasionally, regularly?” Response options
ranged from: (1) “no harm” to (5) “ great harm”(see Appendix D). Items assessing perceived
harmfulness of synthetic marijuana and kratom followed each of the web-discussion forum
scenarios .
Perceived Probability of Experiencing an Adverse Event. A single-item was used to
assess the perceived probability of experiencing and adverse event. Participants responded using
a scale ranging from 0 – 100%. The item assessed the probability (likelihood) of experiencing an
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adverse event using the following format: “On a scale from 0 – 100%, how likely are you to
harm yourself (physically or in other ways) if you…use [substance] once or
twice…occasionally…regularly?” Participants responded using a number from 0-100% (see
Appendices J, K, and L).
Intentions to Use Emerging Substances. A single item was used to assess intentions to
use emerging drugs. Specifically, participants responded to the following item format: “During
the next 12 months how many times do you think you will use [substance]?” Eight response
options included: (1) “Never” (2) “1-2,” (3) “3-5,” (4) “6-9,” (5) “10-19,” (6) “20-29,” (7)
“30-39,” and (8)” 40 or more” (see Appendices J, K, and L).
Subjective Numeracy Scale (SNS). An 8-item measure was used to assess participants’
self-reported numerical ability (Fagerlin, Zikmund-Fisher, Ubel, Jankovic, Derry, & Smith,
2007). Past research has demonstrated adequate internal reliability for this measure (α = .82;
Fagerlin et al., 2007; See Appendix F). Reliability for this measure in the present study was
good (α = .80)
Objective Numeracy Scale (ONS). An 11-item measure was used to assess mathematical
aptitude. Items include questions involving probability, proportions, and percentages. Scores on
the ONS can range from 0 (none correct) to 11 (all correct) with higher scores indicating greater
mathematical ability. Past research has demonstrated adequate internal reliability for this
measure (alpha = .78; Lipkus, Samsa, & Rimer, 2001; see Appendix G). Reliability for this
measure in the present study was approaching adequacy (α = .71)
Preference for Numerical Information. A 20-item measure was used to assess selfreported preference for using numerical information (Viswanathan, 1993).Past research has
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demonstrated adequate internal reliability for this measure (α’s range from .89 - .91). Reliability
for the present study was good (α = 89; See Appendix E).
M-Scale. A 4-item measure was used to assess whether participants were paying attention
to survey items. This measure was also included to examine whether participants were using a
matching strategy of simply repeating the given base-rate information as the likelihood estimate
(Wolfe & Fisher, 2013; See Appendix I).
Brief Sensation Seeking Scale (BSSS). An 8-item forced choice questionnaire was used to
assess self-reported sensation seeking. This measure was included to assess the potential impact
that sensation seeking has on lifetime use of emerging drugs of abuse. The measure includes four
2-item subscales: thrill and adventure seeking (TaAS), experience seeking (ES), disinhibition
(Dis), and boredom susceptibility (BS) (Hoyle, Stephenson, Palmgreen, Pugzles-Lorch, &
Donohew, 2002; Zuckerman, 1996). Higher scores on the subscales and on the 8-item measure
indicate greater levels of sensation-seeking. Past research has demonstrated near adequate
reliability (α= .79; Hoyle et al., 2002). Reliability for subscales in the present study was low
(TaAs = .53; ES = .45; Dis = .58; BS = .32). Reliability for the total overall score in the present
study were approaching adequacy (α = .68). For subsequent analyses the overall score was used.
Web Discussion Task. This task was adapted from Betsch et al. (2012). Participants were
randomly assigned to one of three evidence-type conditions: (1) base-rate information only in
which participants were provided with a single web-posting from a medical doctor describing
base rate data regarding the likelihood of an adverse reaction after using either synthetic
marijuana or kratom (e.g., “400 in 500 individuals who try synthetic marijuana will experience
an adverse reaction”), (2) base-rate information plus positive web-postings in which participants
were provided with the same base rate information described above plus an additional 5 web-
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postings in which 4 web-postings reported positive experiences and 1 web-posting reported a
negative experience (e.g., adverse drug reaction), and (3) base rate information plus negative
web-postings condition in which participants were provided with the same base rate information
described above plus an additional 5 web-postings in which 4 web-postings reported negative
experiences (e.g., adverse drug reactions) and 1 web-posting reported a positive experience (see
Table 4 below).
All participants read two hypothetical web discussion scenarios one scenario involving
synthetic marijuana and the other scenario involving kratom. The presentation of the web
discussion scenarios were counter-balanced so that half of the participants responded to webpostings related to the synthetic marijuana drug scenario followed by web-postings related to
kratom while the other half received these scenarios in reverse order (see Appendix J, K, and L
for an example of task). This was done in order to explore the presence of order effects.
In addition, within each of the three experimental groups (base-rate information only ,
base-rate information plus positive web-postings, and base-rate information plus negative webpostings) the base rates reporting the likelihood of an adverse event were also counter-balanced
such that half of the participants read that the base-rate for having a negative reaction to synthetic
marijuana was 80% (400 out of 500) and the base rate for having a negative reaction to kratom
was 50% (250 out of 500). The other half of the participants read that the base-rate for having a
negative reaction to synthetic marijuana was 50% (250 out of 500) and the base rate for kratom
was 80% (400 out of 500) (See Tables 4 and 5). After participants read each of the web
discussion scenarios they rated the perceived likelihood of experiencing an adverse reaction (for
experimental, occasional, and regular use), perceived harmfulness (for experimental, occasional,
and regular use), and intentions to use the substance in the next 12 months.
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Table 4: Design of Present Study
Experimental Groups
Target Drug

Synthetic
Marijuana*
(e.g., Spice)

Kratom*

Base-Rate Info Only
Condition

80% likelihood of
adverse reaction†

50% likelihood of
adverse reaction†

Base-Rate Info Plus
Positive Web-Postings
Condition

Base-Rate Info Plus
Negative Web-Postings
Condition

80% likelihood of
adverse reaction†

80% likelihood of adverse
reaction†

4 positive reports
1 negative report

4 negative reports
1 positive report

50% likelihood of
adverse reaction†

50% likelihood of adverse
reaction†

4 positive reports
1 negative report

4 negative reports
1 positive report

Key: BR = base-rate; AR = anecdotal reports (i.e., web-postings); * order of presentation
counterbalanced; † base-rates for Spice and Kratom counter-balanced

Table 5 below highlights the sub-groups within each experimental condition. Participants
in Groups 1 through 4 were only provided with base rate information regarding the likelihood of
an adverse event. Participants in Group 5 through 8 were provided with base-rate information
plus primarily positive web-postings. Participants in Groups 9 through 12 were provided with
base-rate information plus primarily negative web-postings . Participants in Group 1 first
completed the web-task related to synthetic marijuana (80% base-rate) and then completed the
web task related to kratom (50% base-rate). The order of presentation of the postings was
reversed for participants in Group 4. Specifically, participants in Group 4 received the web-task
related to kratom (50% base-rate) first followed by synthetic marijuana (80% base-rate).
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For participants in Group 2 and in Group 3, the base-rate information presented for
synthetic marijuana and kratom was switched (relative to Groups 1 and 4). Specifically,
participants in Group 2 received the web-task related to synthetic marijuana (50% base-rate)
followed by kratom (80% base-rate). Participants in Group 3 received the web-task related to
kratom (80% base-rate) followed by synthetic marijuana (50% base-rate). For participants in the
remaining sub-groups within each experimental condition the same counter-balancing strategy
was used. Put another way, participants in Group 1 and Group 4, Group 5 and Group 8, & Group
9 and Group 12 all received base rate information for synthetic marijuana in which there was an
80% likelihood of an adverse reaction; for kratom the base rate was a 50% likelihood of an
adverse reaction. For participants in the remaining groups the base-rate information for synthetic
marijuana and kratom was switched. For example, participants in Group 2 and Group 3, Group 6
and Group 7, & Group 10 and Group 11 all received base rate information for synthetic
marijuana as a 50% likelihood of having an adverse reaction and for kratom as an 80%
likelihood of having an adverse reaction.

Table 5: Base-rate Information Presented by Drug, Experimental Condition, and CounterBalanced Groups Within Experimental Condition
Experimental Condition: Base-Rate Information Only Condition
Drug (Base-Rate)
Drug (Base-Rate)
Group 1:
Spice (80%)
Kratom (50%)a
Group 2:
Spice (50%)
Kratom (80%)b
Group 3:
Kratom (80%)
Spice (50%)b
Group 4:
Kratom (50%)
Spice (80%)a
Experimental Condition: Base-Rate Information Plus Positive Web-Postings Condition
Drug (Base-Rate)
Drug (Base-Rate)
Group 5:
Spice (80%)
Kratom (50%)a
Group 6:
Spice (50%)
Kratom (80%)b
Group 7:
Kratom (80%)
Spice (50%)b
Group 8:
Kratom (50%)
Spice (80%)a

42

Experimental Condition: Base-Rate Information Plus Negative Web-Postings Condition
Drug (Base-Rate)
Drug (Base-Rate)
Group 9:
Spice (80%)
Kratom (50%)a
Group 10:
Spice (50%)
Kratom (80%)b
Group 11:
Kratom (80%)
Spice (50%)b
Group 12:
Kratom (50%)
Spice (80%)a
Note: a and b = not significantly different on main outcome measures within each experimental
condition therefore groups were collapsed for subsequent analyses (described later)
2.3

SELECTION OF WEB-POSTINGS
Web-postings were taken from erowid.org, a website that provides information on

various drugs, their effects, and their current legal status and receives over 13 million unique
visits per year (Erowid, 2014). In addition, hundreds of web-postings describing individuals’
experiences with various drugs are posted in this website. A total of 120 postings were selected
from this website. Thirty postings were selected for each of the following drugs: synthetic
marijuana, kratom, salvia, and OTC medications. For each drug, 15 positive postings were
selected and 15 negative postings were selected. The positive postings used were taken from the
following categories designated in erowid.org: glowing experiences and mystical experiences.
The negative postings used were taken from the following categories designated in erowid.org:
bad trips and difficult experiences. All postings were edited for clarity and were edited to be
approximately ¼ to ½ pages in length.
In order to establish the valence of negative and positive web-postings for use in the
present study a preliminary study was conducted in fall 2013. A total of 278 UTEP
undergraduates (79% Hispanic, 62.6% female) participated in this study. Participants responded
to items assessing demographics, substance use history, familiarity with novel drugs, and
perceived harmfulness of selected novel drugs. Participants then evaluated erowid.org webpostings describing real first-hand experiences with the use of four novel drugs: synthetic
marijuana, salvia, recreational use of OTC medications containing DXM, and kratom.
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Participants evaluated the web-postings along the following dimensions: intensity, positivity, and
negativity. After each web-posting, participants responded to the following item: “We would like
your opinion about the experiences described above. Please indicate how well each of the
following adjectives describes the above experience. Please respond by using the rating scale
below:” Adjectives included the following: (1) intensity, (2) good, (3) pleasant, (4) inviting, (5)
bad, (6) scary, and (7) unpleasant. Seven response options ranged from: (1) “not at all” to
(7)“extremely” (see Appendix M). A composite measure was created for the positive dimensions
such that ratings for good, pleasant, and inviting were averaged to create a “positivity” rating.
Similarly a composite measure was created for the negative dimensions such that ratings for bad,
scary, and unpleasant were averaged to create a “negativity” rating. Values ranged from (1)
“not at all” to (7) “extremely.”
Notably, only two (synthetic marijuana and kratom) of the four drugs evaluated in the
preliminary study yielded ratings for positivity as 3.5 or higher along the positivity dimension
(range : 1 “not at all” to 7 “extremely”) and 3.5 or higher along the negativity dimension (range:
1 “not at all” to 7 “extremely”). As such, the postings related to synthetic marijuana and kratom
were chosen for use in the present study.
Of the web-postings evaluated in the preliminary study, the four most positively rated
positive postings for synthetic marijuana were selected for use in the present study. Similarly, the
four most negatively rated negative postings for synthetic marijuana were selected for use in the
present study. In addition, the four most positively rated positive postings for kratom were
selected for use in the present study. Similarly, the four most negatively rated negative postings
for kratom were selected for use in the present study. The mean ratings for the postings used in
the present study are presented below (see Table 6).
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Table 6: Mean Intensity, Positivity, and Negativity Ratings of Web-Postings Used in the Present Study by
Type of Web-Posting and by Drug
Type of Web-Posting
Positive Spice Postings

Intensity
M(SD)
4.2(0.38)a

Positive Dimension
M(SD)
3.9(0.17)c

Negative Dimension
M(SD)
3.0(0.22)

Positive Kratom Postings

3.6(0.45)b

4.5(0.12)d

2.2(0.19)

Negative Spice Postings

5.6(0.14)a

1.6(0.08)

6.0(0.13)c

Negative Kratom Postings

5.3(0.23)b

1.4(0.38)

5.9(0.13)d

Note: a and b significant at the p < .01 level; c and d significant at the p < .001 level

2.4

PROCEDURE
Participants signed-up for the study via Sona-Systems to schedule a date and time in

which to participate in the study. Survey administration was conducted in available classrooms
located in the Psychology building and was proctored by either an undergraduate research
assistant or myself. Survey administration was conducted in groups in order to facilitate data
collection and increase anonymity of survey responses. Additionally, participants were instructed
to only put their name on the informed consent forms and not on the survey itself to further
ensure anonymity and confidentiality of their responses. Informed consent forms were placed
into an enclosed folder before participants received the first of four survey sections. Each survey
consisted of 4 sections. Once the first section of the survey was completed the participant then
received the subsequent sections until the survey was completed. This was done in order to
reduce burnout on the part of the participant as well as increase vigilance to survey items.
Surveys were sorted randomly prior to the study using random.org. Given that there were 4
permutations within each of the 3 experimental conditions I randomized numbers 1 -12
iteratively in order to guarantee equal cell sizes. Participants received the surveys in the order
participants showed up for the study such that the first participant to show up for the study
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received survey packet 1, the second participant to show up for the study received survey packet
2, and so on.
The first section of the survey packet included the following measures in the following
order: Background Survey I and Perceived Harmfulness Items. The items that assessed perceived
harmfulness for synthetic marijuana and kratom followed the Web Discussion Tasks in the
second section. The second section of the survey packet included the Web-Discussion Forum
Tasks (2 in total). Following each scenario participants responded to items assessing perceived
harmfulness, perceived likelihood of experiencing an adverse event, and intentions to use drug
under consideration. The third section of the survey packet included the following measures in
the following order: Past Experiences with Varied Substances and Background Survey II. The
fourth section included the following measures in the following order: Subjective Numeracy
Scale, Objective Numeracy Scale, Brief Sensation-Seeking Scale, the M-scale, and Familiarity
with Varied Substances Survey. Completion of the surveys took approximately 30 – 45 minutes.
2.5

DESIGN
The study is a mixed 3 X 2 X 2 design with evidence type as the between-subjects factor

(i.e., base-rate information only, base-rate information plus positive web-postings, and base-rate
information plus negative web-postings), base-rate information presented (i.e., 80% versus 50%)
as the between-subjects factor, and the two emerging drug scenarios as the within-subjects factor
(i.e., synthetic marijuana, kratom). Specifically, participants were randomly assigned to one of
three evidence type conditions: (1) a base-rate information only in which participants were
provided with a single web-posting from a medical doctor describing base-rate data depicting the
likelihood of an adverse reaction after using either synthetic marijuana or kratom (e.g., “400 in
500 individuals who try synthetic marijuana will experience an adverse reaction”, (2) a base-
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rate information plus positive web-postings in which participants were provided an identical
web-posting from a medical doctor (described above) plus an additional 5 web-postings in which
4 web-postings report positive experiences and 1 web-posting reporting a negative experience
(e.g., adverse drug reaction), and (3) a base-rate plus negative web-postings in which
participants were provided with an identical web-posting from a medical doctor (described
above)plus an additional 5 web-postings in which 4 web-postings report negative experiences
(e.g., adverse drug reactions) and 1 web-posting reporting a positive experience (See Table 4).
In the base-rate information plus positive web-postings condition the order of the
presentation of web-postings were as follows: positive posting, positive posting, negative
posting, positive posting, and positive posting for both synthetic marijuana and kratom scenarios.
In the base-rate information plus negative web-postings condition the order of the presentation
of web-postings were as follows: negative posting, negative posting, positive posting, negative
posting, and negative posting. The most negative web-posting used in the base-rate information
plus negative web-postings condition was used in the base-rate information plus positive webposting condition. Similarly, the most positive web-posting used in the base-rate information
plus positive web-postings condition was used in the base-rate information plus negative webpostings condition.
2.6

APPROACH TO ANALYSIS
Basic descriptive statistics were conducted to assess characteristics of the sample.

Univariate analyses were conducted to assess the relationships between independent variables
and lifetime use of synthetic marijuana and kratom (0 = never used in lifetime, 1 = used at least
once in lifetime). Chi-square analyses were conducted on the following variables: gender,
lifetime use of cigarettes, lifetime use of marijuana, lifetime use of hookah, and t-tests were
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conducted on the continuous variables sensation seeking and age. A Bonferonni correction was
set used to control for an increase in Type I family-wise error rate (α = .05/ 12 = .004).
Bonferonni was set to p = .004.
2.7

APPROACH TO PRIMARY ANALYSES
Ten 3 X 2 between-subjects ANOVAs were used to the effect of experimental condition

(base-rate information only, base-rate plus positive web-postings, and base-rate plus negative
web-postings) and base-rate information presented (80% versus 50% likelihood of adverse event)
on the following continuous dependent variables for both synthetic marijuana and kratom
scenarios: (1) perceived likelihood of experiencing an adverse event for experimental use, (2)
perceived likelihood of experiencing an adverse event for occasional use, (3) perceived
harmfulness of using substance experimentally, (4) perceived harmfulness of using substance
occasionally, and (5) intentions to use the substance.
Five of the above ANOVAs assessed group differences on the above dependent variables
for synthetic marijuana. Five additional ANOVAs assessed group differences on the above
dependent variables for kratom. Significant results in the ANOVAs were followed up by twotailed post-hoc tests (i.e., Tukey’s HSD) to explore where differences between groups emerged.
A Bonferroni correction was used for the following comparisons between groups on the
following dependent variables (for which there was no explicit hypotheses) in order to control
for an increase in the Type I family-wise error rate: (1) perceived harmfulness of using substance
experimentally, (2) perceived harmfulness of using substance occasionally, and (3) intentions to
use substance. A total of 12 comparisons were made; therefore the Bonferroni correction set the
p-value at .004. A Bonferroni correction was also used for the following comparisons between
groups on the following dependent variables: (1) perceived likelihood of experiencing an adverse
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event for experimental use and (2) perceived likelihood of experiencing an adverse event for
occasional use. A total of 8 comparisons of these were made; therefore the Bonferonni correction
set the p-value at .006.
2.8

APPROACH TO TESTING ASSUMPTIONS IN PRIMARY ANALYSES
Analyses were conducted in order to test for any potential violations in assumptions in

ANOVA. In order test for univariate normality in the dependent variables, K-S tests were
conducted. If the K-S tests are not significant (alpha = .05), then the scores on the dependent
variables are not significantly different from a normal distribution. However, K-S tests can
produce significant findings with large sample sizes in the absence of violations of normality
(Field, 2013). Therefore, a second strategy was also used. Specifically, visual inspections of QQ plots were also used to assess normality of the distribution of scores of the continuous
dependent variables. K-S tests reached statistical significance in the dependent measures (p’s <
.001); therefore univariate normality in the dependent measures was violated. Visual inspection
of the Q-Q plots confirmed this violation.
Levene’s tests were used in order to test for potential violations in equality of variances
between groups on the dependent measures. If the Levene’s tests are not significant, then the
variance in scores on the dependent variables between groups can be assumed to be equal.
Violations, however, were observed for 7 out of 10 outcome variables including:(1) likelihood of
experiencing an adverse reaction to experimental use of synthetic marijuana, F(5,446) = 3.89, p
=.002, (2) perceived harmfulness for occasional use of synthetic marijuana, F(5,446) = 2.44, p =
.033, (3) intentions to use synthetic marijuana in the next 12 months, F(5,446) = 3.61, p = .003,
(4) likelihood of experiencing an adverse reaction to experimental use of kratom, F(5,446) =
5.48, p < .001. (5) likelihood of experiencing an adverse reaction to occasional use of kratom,
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F(5,446) = 2.67, p = .003, (6) perceived harmfulness for experimental use of kratom, F(5,444) =
2.52, p = .029, (7) intentions to use kratom in the next 12 months, F(5,445) = 2.62, p = .023.
2.9

APPROACH TO SECONDARY ANALYSES
The impact of numeracy on the relative importance of statistical and anecdotal evidence

on perceived likelihood of experiencing an adverse event was assessed using three strategies.
First, four hierarchical linear regressions were conducted with perceived likelihood of
experiencing an adverse event for experimental use of synthetic marijuana and kratom as the
criterions. In the first step, scores on a measure of numerical ability (i.e. ONS) were entered. In
the second step, group membership was entered. This analysis allowed for an exploration of the
effect of group membership on likelihood ratings after accounting for the effect of numerical
ability on likelihood ratings.
In the analyses described above normality in the continuous independent variable,
numeracy scores (i.e. ONS scores), was assessed using recommendations set forth by Cohen,
Cohen, West, & Aiken (2003). No violations in normality were found in the continuous variable
ONS scores used in hierarchical regression analyses (described above) as evidenced by values of
skewness < 2 and kurtosis < 10. Multicollinearity between the two predictors (ONS scores and
experimental condition) was assessed using the variance inflation factor score. Multicollinearity
is typically assumed to be present when the VIF score exceeds the value of 10. In the current
study the VIF was less than 10. This, however, does not necessarily suggest that multicollinearity
is not present as lower values may still indicate the presence of multicollinearity. Thus, the
results should be interpreted with caution.
Second, correlations were used to assess whether individuals with limited numerical
ability display an increased reliance on narrative evidence and a decreased reliance on statistical
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evidence when evaluating risk of using emerging drugs. Specifically, a deviation score was
created for each participant by subtracting an individual’s perceived likelihood rating from the
given base-rate information. For example, a participant randomly assigned to the base-rate
information only condition may read that 50% of individuals experience an adverse reaction as a
result of using kratom. This participant may then rate the likelihood of experiencing an adverse
event as 40%. The deviation score for this individual would be 10% (50% - 40%). Deviations
scores were also calculated for individuals assigned to the remaining conditions (base-rate
information plus positive web-postings condition and base-rate information plus negative webpostings condition). Once deviation scores were calculated for each participant in each condition,
correlations were conducted. Before correlational analyses were conducted, deviation scores
were converted into absolute values. If individuals with limited numerical ability are more
influenced by anecdotal information and less influenced by statistical information when
evaluating the risks of ‘emerging’ drugs,” then the deviation score of a highly numerate
individual should be smaller than for a less numerate individual. Significant negative
correlations between the variables numeracy scores and deviation scores would indicate that as
numeracy decreases there is a greater amount of departure from the given base-rate information.
This pattern of results would suggest that less numerate individuals are more influenced by
narrative evidence than base rate information when evaluating the likelihood of experiencing an
adverse event.
A third strategy was used to explore the interaction of Experimental Group and
Numeracy scores (as measured by the ONS) using a hierarchical regression framework. In these
latter analyses, perceived likelihood of experiencing an adverse event for experimental use of
synthetic marijuana and kratom were the dependent variables. A total of 4 of these hierarchical
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regressions were conducted. In the first step, lifetime use of synthetic marijuana or kratom was
entered. In the second step, the experimental grouping variables were entered. In the third step,
numeracy scores were entered. In the fourth step, experimental group X numeracy score
interaction terms were entered.
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Chapter 3: Results
3.1

PARTICIPANT CHARACTERISTICS
Tables 7 through 12 summarize the characteristics of the sample. The mean age of the

sample was 19.6 (SD = 2.15) and the sample was comprised of 84.5% Hispanics. Females
comprised the majority of the sample (59.0%) and the majority of the participants were college
Freshmen (51.2%). In addition, the majority of the sample grew up in El Paso, TX (74.3%).
High levels of lifetime use of alcohol (91.4%), cigarettes (58%), hookah (61.9%), and marijuana
use (52.7%) were reported. Non-trivial rates of lifetime use of cocaine (8.8%), hallucinogens
(8.2%), synthetic marijuana (11.9%) and abuse of OTC medications (12.6%) were reported in
the sample. The majority of participants reported familiarity with hookah tobacco (92.2%),
synthetic marijuana (76.9%), and recreational use of OTC medications (89.8%). Forty-seven
(47.7%) of participants reported familiarity with salvia and 8.9% reported familiarity with
kratom.
Table 13 provides the percentage of participants indicating “great harm” for
experimental, occasional, and regular use of each substance. Perceived harm was low for
experimental, occasional, and regular use of marijuana (6.6%, 10.0%, and 25.5%, respectively).
Similarly, perceived harm was also low for experimental, occasional, and regular use of hookah
tobacco (3.3%, 5.1%, and 21.5%).
Table 14 provides the participants’ composite scores on three measures of numeracy or
numerical ability: the Subjective Numeracy Scale (SNS), the Objective Numeracy Scale (ONS),
and Preference for Numerical Information. Self-reported numeracy, as measured by the SNS,
was close to the mid-point of the scale (M = 4.27, SD = .90; range: 1 – 8). In addition, scores on
the Objective Numeracy Scale were low (M = 6.65, SD = 2.41; range: 0-11). Participants, on
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average, also indicated a slight preference for numerical information (M = 3.36, SD = .91; range:
1 – 7 where lower scores indicate a greater preference for numerical information).
3.2

PRELIMINARY ANALYSES
The following variables were found to be associated with lifetime use of synthetic

marijuana: lifetime use of cigarettes, X2 (1) = 24.07, p < .001, lifetime use of marijuana, X2 (1) =
42.96, p < .001), and lifetime use of hookah, X2 (1) = 27.47, p < .001.
The following variables were found to be associated with lifetime use of salvia: lifetime
use of marijuana X2 (1) =20.79, p < .001 and lifetime use of hookah X2 (1) = 11.01, p < .001.
The following variables were found to be associated with lifetime abuse of OTC
medications: lifetime use of cigarettes X2 (1) = 16.05, p < .001 and lifetime use of marijuana X2
(1) = 20.58, p < .001. The following continuous variable was found to be associated with lifetime
abuse of OTC medications: sensation seeking, t(450) = -3.52, p < .001
Univariate analyses were not conducted on lifetime use of kratom because no participants
reported lifetime use of kratom.
No significant differences were found between experimental conditions on self-reported
lifetime use of all substances assessed. More specifically, no significant differences in lifetime
use of alcohol, cigarettes, cocaine, hallucinogens, heroin, hookah, kratom, marijuana,
methamphetamine, OTC medication, salvia, or synthetic marijuana were found between
experimental conditions (p’s > .05).
No significant differences were found on numeracy scores (as measured by the ONS)
between experimental conditions, F(450) = 2.75, p = .064. However, significant differences on
numeracy scores were found between women and men with men scoring significantly higher on
the ONS than women, t(449) = -5.08, p < .000; Mmen = 7.54, Mwomen = 6.41).
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Inter-correlations among dependent measures used in the primary analyses are displayed
in Table 31.
The percentage of participants scoring 0, 1, 2, 3, and 4 items correct in the M-Scale
measure are presented in Table 32. Notably, 7.7% (n = 35) of participants scored a zero
indicating participants’ may not have been paying attention to M-Scale items. Table 33 presents
the percentage of participants’ incorrect responses on the M-Scale by item as well as the
percentage of participants’ incorrect mirror responses by item. Notably, 0.7% (n = 3) of
participants responded incorrectly by simply repeating the given base-rate information presented
in the M-Scale scenarios (See Appendix I). Future studies would benefit from investigating the
appropriate cut-off score for determining which participants (if any) should be removed from a
dataset due to inattention and potential response bias.
3.3

PRIMARY ANALYSES: EFFECT OF EXPERIMENTAL GROUP
MANIPULATION
Separate univariate ANOVAs revealed significant main effects of experimental group on

the following dependent variables: (1) likelihood of experiencing an adverse reaction for
experimental use of synthetic marijuana, F(2,446) = 31.00, p < .001, (2) likelihood of
experiencing an adverse reaction for occasional use of synthetic marijuana F(2,446) = 18.14, p <
.001, (3) perceived harmfulness of experiencing an adverse reaction for experimental use of
synthetic marijuana, F(2,446) = 40.19, p < .001,, and (4) perceived harmfulness of experiencing
an adverse reaction for occasional use of synthetic marijuana, F(2,446) = 22.30, p < .001.
Separate univariate ANOVAs revealed significant main effects of experimental group on the
following dependent variables: (1) likelihood of experiencing an adverse reaction for
experimental use of kratom, F(2,446) = 24.23, p < .001, (2) likelihood of experiencing an
adverse reaction for occasional use of kratom F(2,446) = 17.74, p < .001 , (3) perceived
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harmfulness of experiencing an adverse reaction for experimental use of kratom F(2,444) =
46.88, p < .001, and (4) perceived harmfulness of experiencing an adverse bad reaction for
occasional use of kratom F(2,445) = 33.97, p <.001.
Two-tailed post-hoc analyses were conducted to determine the source of these
differences. Likelihood of harm ratings for experimental use of Spice was significantly higher in
the base-rate information plus negative web-postings condition relative to the base-rate
information only condition (p < .006). Additionally, likelihood of harm ratings for experimental
use of synthetic marijuana was significantly higher in the base-rate information plus negative
web-postings condition relative to the base-rate plus positive web-postings condition (p < .006).
No significant differences were found for likelihood ratings for experimental use of synthetic
marijuana between the base-rate information plus positive web-postings condition and the baserate information only condition (See Table 15).
Likelihood of harm ratings for the occasional use of synthetic marijuana was significantly
higher in the base-rate information plus negative web-postings condition relative to the base-rate
information only condition. Additionally, likelihood of harm ratings for occasional use of
synthetic marijuana was significantly higher in the base-rate information plus negative webpostings condition relative to the base-rate information plus positive web-postings condition. No
significant differences in likelihood of harm ratings for occasional use of synthetic marijuana
was found between the base-rate information only condition and the base-rate information plus
positive web-postings condition (See Table 15)
Likelihood of harm ratings for experimental use of kratom was significantly higher in the
base-rate information plus negative web-postings condition relative to the base-rate information
only condition. Additionally, likelihood of harm ratings for experimental use of kratom was
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significantly higher in the base-rate information plus negative web-postings condition relative to
the base-rate information plus positive web-postings condition. No significant differences were
found for likelihood ratings for experimental use of kratom between the base-rate information
plus positive web-postings condition and the base-rate information only condition (See Table
16).
Likelihood of harm ratings for the occasional use of kratom was significantly higher in
the base-rate plus negative web-postings condition relative to the base-rate only condition.
Additionally, likelihood of harm ratings for occasional use of kratom was significantly higher in
the base-rate information plus negative web-postings condition relative to the base-rate
information plus positive web-postings condition. No significant differences in likelihood of
harm ratings for occasional use of kratom were found between the base-rate information only
condition and the base-rate information plus positive web-postings condition (See Table 16).
No significant differences were found on intentions to use synthetic marijuana or kratom
between any of the experimental conditions (See Tables 19 and 20). Differences in perceived
harmfulness between the groups are displayed in Tables 17 and 18. Notably, when comparing
perceived harmfulness ratings to perceived likelihood of harm ratings (described above) a similar
pattern emerged between the base-rate plus negative web-postings condition relative to the base
rate only condition such that perceived harmfulness was significantly greater in the base-rate
plus negative web-postings condition relative to the base-rate only condition. In one instance,
however, perceived harmfulness of using kratom occasionally was significantly lower in the
base-rate plus positive web-postings condition relative to the base-rate only condition (See
Tables 17 and 18).
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3.4

PRIMARY ANALYSES: EFFECT OF BASE-RATE INFORMATION
PRESENTED (80% VS. 50%)
Correcting for multiple comparisons (p = .005), there was a significant main effect of

base-rate information presented (80% vs. 50%) on likelihood of experiencing an adverse event
for the experimental use of kratom, F(1,446) = 8.63, p = .003. Individuals presented with baserate information stating an 80% likelihood of experiencing an adverse event rated the likelihood
of experiencing an adverse event for experimental use as 44.1% whereas individuals presented
with base-rate information stating a 50% likelihood of experiencing an adverse event rated the
likelihood of experiencing an adverse event as 35.8% (p = .003).
3.5

ANALYSES TO EXAMINE IMPACT OF NUMERACY ON LIKELIHOOD OF
HARM RATINGS
In the first approach, four hierarchical linear regressions were conducted to examine if

numeracy scores were associated with perceived likelihood of harm for experimental use of
synthetic marijuana and kratom. The dependent measures were as follows: perceived likelihood
of harm for experimental use of synthetic marijuana (Grouping 1), perceived likelihood of harm
for experimental use of kratom (Grouping 1), perceived likelihood of harm for experimental use
of synthetic marijuana (Grouping 2), and perceived likelihood of harm for experimental use of
kratom (Grouping 2). In the first step of these hierarchical linear regressions scores on the ONS
were entered. In the second step, experimental group was entered. In all four of these
hierarchical linear regressions ONS scores were not statistically significant and, therefore,
numeracy did not account for a significant amount of variance in likelihood of harm ratings (See
Tables 21 through 24).
In the second approach, 4 bivariate correlations assessed the relationship between
numerical ability and deviation scores. No significant associations were found between deviation
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scores and numeracy scores; therefore numerical ability did not influence the degree to which
one’s perceived likelihood of harm rating deviates from the stated base-rate information (See
Tables 25 and 26).
In the third approach, four moderation analyses were conducted. The dependent
variables for these analyses were as follows: (1) likelihood of harm for experimental use of
synthetic marijuana (for collapsed groups 1 and 4, 5 and 8, & 9 and 12 or Grouping 1), (2)
likelihood of harm for experimental use of synthetic marijuana (collapsed groups 2 and 3, 6 and
7, & 10 and 11 or Grouping 2), (3) likelihood of harm for experimental use of kratom (for
collapsed groups 1 and 4, 5 and 8, & 9 and 12 or Grouping 1), and (4) likelihood of harm for
experimental use of kratom (collapsed groups 2 and 3, 6 and 7, & 10 and 11 or Grouping 2) .
In the first regression, controlling for lifetime use of synthetic marijuana, no significant
main effects of numeracy scores were observed. Moreover, the Experimental Group X
Numeracy interaction terms were non-significant. Therefore numeracy scores did not moderate
the relationship between Experimental Group and likelihood of harm ratings for synthetic
marijuana. As such, follow-up Brown-Forsythe analyses were not conducted. However, lifetime
use of synthetic marijuana was significantly associated with likelihood of harm ratings for
experimental use of synthetic marijuana (p < .05) such that lifetime use of synthetic marijuana
was associated with lower likelihood of harm ratings for experimental use (See Table 27).
In the second regression, controlling for lifetime use of synthetic marijuana, no
significant main effects of numeracy scores were observed. Similar to the previous analyses, the
Experimental Group X Numeracy interaction terms were non-significant. Therefore numeracy
scores did not moderate the relationship between Experimental Group and likelihood of harm
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ratings for synthetic marijuana. As such, follow-up Brown-Forsythe analyses were not conducted
(See Table 28).
In the third regression, no significant main effect of numeracy scores was observed.
Moreover, the Experimental Group X Numeracy interaction terms were non-significant.
Therefore numeracy scores did not moderate the relationship between Experimental Group and
likelihood of harm ratings for kratom. As such, follow-up Brown-Forsythe analyses were not
conducted (See Table 29).
In the fourth regression, no significant main effect of numeracy scores was observed.
Moreover, the Experimental Group X Numeracy interaction terms were non-significant.
Therefore numeracy scores did not moderate the relationship between Experimental Group and
likelihood of harm ratings for kratom. As such, follow-up Brown-Forsythe analyses were not
conducted (See Table 30).
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Chapter 4: Discussion
Findings from the current study suggest that young adults are very familiar with
emerging drugs of abuse. Moreover, a sizable percentage of participants reported lifetime use of
synthetic marijuana, salvia, and recreational use of OTC medications. Although the sample may
not be representative of the U.S. college student population, such use rates have implications for
public health. For example, given that approximately 18 million young adults are enrolled in
post-secondary education, findings from the present study suggest that over 2 million young
adults will experiment synthetic marijuana and OTC medications in their lifetime and over
800,000 young adults will experiment with salvia in their lifetime (U.S. Department of
Education, 2013). This is especially troubling given the legal status of salvia in many U.S. states
and the high availability of OTC medications and synthetic marijuana. This is also particularly
disconcerting given that use of synthetic marijuana and recreational use of OTC medications can
be life-threatening.
Perceived harmfulness for the use of emerging drugs was also low. Indeed, the
percentage of students in the current sample who reported that experimental use of salvia would
lead to “great risk” was strikingly lower than the percentage of students ages 19 – 22 in the 2012
MTF survey who stated that experimental use of salvia would lead to “great risk” (11.8 % vs.
39.4%, respectively; Johnston et al., 2013). Perceived harmfulness for experimental use of OTC
medication reported in the present sample was also lower (11.5% indicating “great risk”)
compared to recent MTF survey data for 10th graders (23.6% indicating “great risk”; Johnston et
al., 2013). This pattern suggests that when high school students transition into higher education,
risk perceptions for the use of drugs decrease. This is likely to place individuals at an increased
risk for the use of emerging drug of abuse as well as other drugs of abuse. Indeed, recent MTF

61

data suggests that as adolescents transition into young adulthood, perceptions of risk for the
experimental use of marijuana decrease. For example, 26% of 8th graders reported “great risk”
for the experimental use of marijuana whereas only 17.2% of 10th graders and 14.8% of 12th
graders reported “great risk” for the experimental use of marijuana (Johnston et al., 2013).
Though these data are cross-sectional, the pattern suggests that perceptions of harm decrease as
young adults transition to higher education.
4.1

THE ROLE OF NARRATIVE VERSUS STATISTICAL EVIDENCE
Findings from the present study suggest that individuals do not inevitably fall prey to

base-rate neglect. Indeed, findings from the present study support the opposite conclusion: baserate information influences perceived likelihood of harm when the risk of harm is high. Some
participants in the study were presented with base-rate information highlighting the likelihood of
experiencing an adverse reaction after using synthetic marijuana, while other participants were
provided with base-rate information and several personal anecdotes describing positive drug
experiences after using synthetic marijuana. Base-rate neglect would predict that participants in
the latter condition would rate synthetic marijuana use as less harmful than participants who
were only exposed to base-rate information. However, the present study failed to reveal group
differences in perceived harm and perceived likelihood of harm between participants in the base
rate only condition and participants in the base-rate plus positive web-reports condition. This
finding is consistent with Bar-Hillel’s (1980) suggestion that people do not ignore base-rate
information when the base-rate information is relevant to the judgment they are making. Given
that participants were asked to rate the risk associated with using emerging drugs, the base-rate
information highlighting the likelihood of harm was perceived as relevant to their evaluations.
As such, the given base-rate information was not ignored.
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Notably, the present study did reveal a form of base-rate neglect when participants were
provided with several personal anecdotes describing negative drug experiences. Participants
presented with both base-rate information and negative anecdotes significantly magnified the
risk and likelihood of harm relative to participants presented with only base-rate information.
However, participants may not be ignoring base-rate information so much as using the given
base-rate information as an anchoring point; one in which they adjust upward as a result of being
presented with negative anecdotal reports. Perhaps, when the degree of negative consequences is
severe (e.g., overdose, death) and the potential benefits are low (e.g., warm fuzzy feelings)
individuals are more likely to err on the side of caution and judge the risk of harm and likelihood
of harm as even higher.
Interestingly, in one instance, the effect of positive web-postings in reducing perceived
harmfulness (relative to the base-rate only condition) was observed. Specifically, web-postings
describing positive experiences with kratom significantly reduced participants’ perceived
harmfulness for the occasional use of kratom. This finding might also suggest the presence of
base-rate neglect. Notably, familiarity with kratom was low relative to familiarity with synthetic
marijuana. Perhaps, when familiarity with a novel drug is low the effect of positive postings in
reducing perceived harmfulness may be greater. Future research should examine whether there
is a greater effect of positive anecdotal reports in reducing perceived harmfulness when a drug is
less familiar relative to more familiar drug.
4.2

INFORMATION PROCESSING, NARRATIVE EVIDENCE, AND HEURISTIC
BIASES
In his book, “Thinking, fast and slow,” Kahneman (2011) suggests that there are two

independent but interacting mechanisms by which individuals process information. One of these
mechanisms, which Kahneman describes as “System 1”, is associated with automatic processing.
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This automatic processing can lead to systematic errors in judgment and is prone to heuristic
biases, such as the availability heuristic and the representativeness heuristic. The other
mechanism for processing information Kahneman describes as “System 2” and is associated with
deliberate, analytical, information processing.
Other authors generally agree that there are two systems for information processing. For
example, Bekker, Winterbottom, Butow, Dillard, Feldman-Stewart, Fowler, et al. (2013) states
the following, “…[e]xplanations of how people process information to make decisions generally
agree that there are two inter-related systems used: an experiential-automatic process (system 1)
that is quick, effortless, and does not require deliberation before action (e.g., relying on a
heuristic or rule of thumb such as trust in another’s judgments); and an analytic-deliberative
process (system 2) that is effortful, cognitively demanding, and requires active reasoning before
action (e.g., weighing up the advantages and disadvantages of all options).” Interestingly,
individuals tend, in general, to rely largely on System 1 processing and utilize System 2
processing only when necessary. Kahneman (2011) terms this general proclivity as the lazy
controller.
Notably, past research has suggested that inclusion of narrative information encourages
heuristic rather than deliberate systematic processing (Winterbottom, Bekker, Conner, &
Mooney, 2008). Heuristic processing has been associated with errors in judgment including a
tendency to overweight narrative evidence and underweight statistical information, such as baserate information, when making decisions under uncertainty. Other pitfalls of relying on heuristic
processing include: (1) a tendency to overweight low probabilities and underweight high
probabilities, (2) a narrow framing of decision problems, and (3) a pronounced reaction to losses
relative to gains. Heuristic processing may explain, in part, individuals’ tendency to ignore base-
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rate information when individuals are provided with narrative evidence. Moreover, given that
heuristic processing is associated with a pronounced reaction to losses (rather than gains), it
could be that negative anecdotal reports that participants read in the present study primed
heuristic processing to a greater extent than did positive narrative reports. This may explain the
differences found in risk perception between individuals in the base-rate plus negative webpostings condition and the base-rate only condition and the lack of differences between the baserate plus positive web-postings condition and the base-rate only condition. An alternative
explanation might be that the positive postings were not nearly as positive as the negative
postings were negative. Assuming the postings were more positive, the effect of positive
postings in reducing risk perceptions may have been observed.
Another potential explanation for the differences found in risk perception between
individuals in the base-rate plus negative web-postings condition and the base-rate only
condition and the lack of differences between the base-rate plus positive web-postings condition
and the base-rate only condition might be related to the vividness of the narratives. Although
vividness in the present study was not assessed, it may be reasonable to assume that the negative
web-postings were more vivid than the positive postings given that they elicited higher intensity
ratings. Notably, it has been suggested that vividly-presented information can be more persuasive
(Nisbett & Ross, 1980).
It is important to note that the negative anecdotes used in the present study were intense
and often “brutal” and “disturbing” to read. The intensity and vividness of these anecdotes lies
in stark contrast to the dry and non-vivid information presented in the base-rate web-postings.
Perhaps, if the base-rate information was presented as intensely as the negative anecdotal reports
differences in perceived harm and likelihood of harm between the base-rate only condition and
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the base-rate plus negative web-postings condition may not have been observed. Future research
would benefit from addressing this issue.
4.3

NARRATIVE EVIDENCE, DECISION-MAKING, AND IMPLICATIONS FOR
DRUG PREVENTION
Few studies have directly compared the combined effect of base-rate information and

anecdotal information on decision-making and related processes. Those studies that have
examined the relative impact of base-rate information and anecdotal information have done so
almost exclusively in the context of medical decision making. These latter studies generally
examine whether inclusion of narratives in patient decision aids (PtDAs) either helps or hinders
one’s ability to make informed decisions. A recent review concluded that there is insufficient
evidence to support the conclusion that the inclusion of personal stories improves informed
decision-making capacity (Bekker et al., 2013). Moreover, Bekker et al. (2013) concluded that it
is unclear whether the inclusion of narratives improves decision making in health contexts.
In the context of drug prevention, however, the goal is not necessarily to improve
decision making but rather to increase perceptions of risk. Results from the current study are
promising from a social marketing standpoint. For example, findings from the current study
suggest that risk communications designed to prevent young adults’ experimentation with
emerging drugs would benefit by including reports that describe negative drug experiences to
base-rate information that highlight the risks of using emerging drugs. Moreover, findings from
the present study suggest that risk communications that include a positive anecdotal report will
not soften the impact of negative anecdotal reports on risk perceptions. This might be
particularly important for risk communications that want to promote a more balanced, two-sided
prevention message. Such messages may be perceived as less coercive and authoritarian by
young adults and may lead to less psychological reactance.
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4.4

STRENGTHS
Few studies have examined decision-making and related processes (e.g., attitudes, risk

perception) when individuals’ are given both statistical information (i.e., base-rate) and anecdotal
information. This study contributes to this growing body of research. Moreover, we know of no
studies that have examined how individuals’ weigh these latter forms of evidence in the context
of emerging drug use. This study addresses an important gap in research as it is very likely that
every generation will face an emerging drug of abuse. Moreover, this study utilized real webpostings that were taken from erowid.org, a website that generate over 85,000 unique visits per
day and over 13 million unique visits per year (Erowid, 2014). Studying the impact of webpostings on social media may be particularly important given that young adults’ may be more
inclined to utilize social media when evaluating the risks associated with emerging drugs.
In addition, this study included postings related to the use of synthetic marijuana, a drug
that has only been in the United States since 2008 (DEA, 2012). Since that time use of synthetic
marijuana has increased rapidly and is only now beginning to show signs of abating. The present
study found that familiarity of synthetic marijuana was high and non-trivial lifetime and past
year use rates were observed. As such, this study provides a good litmus test for how young
adults weigh both statistical and anecdotal information for an emerging drug that people are
highly aware of. Moreover, the present study also included postings related to the use of kratom,
an emerging drug for which, in the current sample, there was little awareness. Furthermore, no
one in the current sample reported lifetime use of kratom. Therefore, this study also provides an
excellent litmus test for how young adults weigh statistical and anecdotal evidence for a drug
that just “came on the scene.”
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4.5

LIMITATIONS
There are several limitations to this study. First, generalization of the findings to other

populations may be limited given that the participants in the sample were primarily Freshmen
and Sophomore Hispanic college students. This constraint may limit the extent to which
findings may generalize to older, non-Hispanics, and/or young adults who do not enroll in higher
education. Second, given that the present study assesses use of drugs (legal, quasi-legal, or
otherwise) via a self-report there is the possibility that participants may be under-reporting
substance use. Additionally, given that there was no follow-up assessment of perceptions of
harm, perceived likelihood of harm, and intentions to use synthetic marijuana and kratom
nothing can be said about the stability of these perceptions over time. Lastly, the current findings
do not permit an investigation of the relationship between perceived harm and behavioral
intentions. Prior research has revealed an association between drug use and perceived harm: as
perceived harm increases self-reported drug use decreases. For example, data from the
Monitoring the Future (MTF) surveys clearly depicted this relationship (Bachman et al., 1988). It
is important to note however that correlation does not indicate causation. In the present study
only a few individuals reported intentions to use synthetic marijuana and kratom. For this reason
it was not possible to examine the potential moderating or mediating effects of perceived harm
between the variables experimental condition and intentions.
4.6

FUTURE DIRECTIONS
Future research should build on the present study by examining how young adults weigh

both base-rate and anecdotal information in the context of other emerging drugs including
synthetic cathinones (also known as “bath salts) as well as other drugs such as marijuana, which
may be an especially salient topic given its recent legal status in Colorado and Washington.
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Moreover, this line of research may be especially important to pursue in the context of modified
risk tobacco products (e.g., E-cigarettes, Snus, Orbs, etc.). This is important given that little is
known about how young adults evaluate the risks associated with the use of modified risk
tobacco products much less how they weigh statistical and anecdotal when evaluating those
risks.
Future research should also build on the present study by varying the number of positive
and negative anecdotes as well as systematically varying the degree of intensity and the degree
of positivity and negativity of the web-postings. Such research would help address what might
be akin to an exchange rate, one that answers the following questions: (1) How many positive
postings does it take to undermine base-rate information highlighting the risks associated with
using a particular substance?, (2) How many negative postings does it take to maximize the
perceived risks associated with using a particular substance?, and (3) What might be the socalled magic number of negative postings or ratio of negative postings to positive postings that
would maximize one’s perceptions of risk for the use of a particular substance?
Even if these latter questions are answered, this “exchange rate” may be domain-specific
or even drug-specific given that the range experiences varies by drug and decisions to use a
substance are very different from making other decisions that can impact your health (e.g.,
deciding to undergo a particular treatment). Future research should also consider examining how
individuals weigh the relative impact of statistical and anecdotal evidence by using video
testimonials of individuals describing their first hand experiences with emerging drugs. This
would shed light on the relative impact of different forms of testimonials on one’s evaluation of
risk. Lastly, future research may also consider using third-person narratives to assess the impact
that third-person narratives has on an individuals’ evaluation of risk for an emerging substance.
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This may be particularly important given that for an emerging drug someone may hear of
another’s drug experience through a friend.
4.7

CONCLUDING REMARKS
The research community, public health community, and those individuals who are

interested in drug prevention should not ignore the use of legal, quasi-legal, or emerging drugs.
Non-trivial lifetime and past year use rates of synthetic marijuana, salvia, and abuse of OTC
medications were reported in this sample as well as in nationally representative samples.
Targeted prevention efforts should focus on young men and women who report lifetime use of
cigarettes, hookah, and marijuana and those with higher levels of sensation-seeking. Developers
of prevention messages targeting emerging drugs should consider incorporating real first-person
testimonials of individuals reporting negative drug experiences when providing base-rate
information that highlights the risks associated with the use of emerging drugs.
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Table 7: Participant Characteristics
Variable
Age

n

%

450

Gender
Males

185

41.0%

Females

266

59.0%

Hispanic

382

84.5%

White

27

6.0%

African American

10

2.2%

Asian American

8

1.8%

Native American

2

0.4%

Other

23

5.1%

Freshmen

231

51.2%

Sophomores

118

26.2%

Juniors

76

16.9%

Seniors

23

5.1%

Not Sure

3

0.7%

Ethnicity

College Level

79

M

SD

19.60

2.15

Table 8: Participant Characteristics (continued)
Variable

n

%

M

El Paso, TX

335

74.3%

Juarez, Mexico

50

11.1%

Las Cruces, NM

1

0.2%

El Paso/Juarez

3

0.7%

El Paso/Other

1

0.2%

Other

61

13.5%

Birthplace

80

SD

Table 9: Participant Characteristics (continued)
Lifetime Use for each Drug

n

%

Alcohol Use
Alcohol Non-Use

413
39

91.4%
8.6%

Cigarette Use
Cigarette Non-Use

262
190

58.0%
42.0%

Cocaine Use
Cocaine Non-Use

40
412

8.8%
91.2%

Hallucinogen Use
Hallucinogen Non-Use

37
415

8.2%
91.8%

Heroin Use
Heroin Non-Use

3
449

0.7%
99.3%

Hookah Use
Hookah Non-Use

280
172

61.9%
38.1%

Kratom Use
Kratom Non-Use

0
452

0.0%
100.0%

Marijuana Use
Marijuana Non-Use

238
214

52.7%
47.3%

Methamphetamine Use
Methamphetamine Non-Use

4
448

0.9%
99.1%

Methaqualone Use
Methaqualone Non-Use

0
452

0.0%
100.0%

OTC Medication Abuse
OTC Medication Non-Abuse

57
395

12.6%
87.4%

Salvia Use
Salvia Non-Use

22
430

4.9%
95.1%

Synthetic Marijuana Use
Synthetic Marijuana Non-Use

54
398

11.9%
88.1%
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Table 10: Participant Characteristics (continued)
Past Year Use for each Drug

n

%

Alcohol Use
Alcohol Non-Use

388
64

85.8%
14.2%

Cigarette Use
Cigarette Non-Use

187
265

41.4%
58.6%

Cocaine Use
Cocaine Non-Use

23
429

5.1%
94.9%

Hallucinogen Use
Hallucinogen Non-Use

16
436

3.5%
96.5%

Heroin Use
Heroin Non-Use

0
452

0.0%
100.0%

Hookah Use
Hookah Non-Use

236
216

52.2%
47.8%

Kratom Use
Kratom Non-Use

0
452

0.0%
100.0%

Marijuana Use
Marijuana Non-Use

186
266

41.2%
58.8%

Methamphetamine Use
Methamphetamine Non-Use

0
452

0.0%
100.0%

Methaqualone Use
Methaqualone Non-Use

0
451

0.0%
100.0%

OTC Medication Abuse
OTC Medication Non-Abuse

32
420

7.1%
92.9%

Salvia Use
Salvia Non-Use

3
449

0.7%
99.3%

Synthetic Marijuana Use
Synthetic Marijuana Non-Use

18
434

4.0%
96.0%

82

Table 11: Participant Characteristics (continued)
Past 30-Day Use for each Drug

n

%

Alcohol Use
Alcohol Non-Use

293
159

64.8%
35.2%

Cigarette Use
Cigarette Non-Use

102
350

22.6%
77.4%

Cocaine Use
Cocaine Non-Use

8
444

1.8%
98.2%

Hallucinogen Use
Hallucinogen Non-Use

3
449

0.7%
99.3%

Heroin Use
Heroin Non-Use

0
452

0.0%
100.0%

Hookah Use
Hookah Non-Use

114
338

25.2%
74.8%

Kratom Use
Kratom Non-Use

0
452

0.0%
100.0%

Marijuana Use
Marijuana Non-Use

100
352

22.1%
77.9%

Methamphetamine Use
Methamphetamine Non-Use

0
452

0.0%
100.0%

Methaqualone Use
Methaqualone Non-Use

0
449

0.0%
100.0%

OTC Medication Abuse
OTC Medication Non-Abuse

9
443

2.0%
98.0%

Salvia Use
Salvia Non-Use

0
452

0.0%
100.0%

Synthetic Marijuana Use
Synthetic Marijuana Non-Use

3
445

0.7%
99.3%
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Table 12: Participant Characteristics (continued)
Familiarity with each Drug

n

%

Alcohol

446/451

98.9%

Cigarettes

446/451

98.9%

Cocaine

440/451

97.6%

Hallucinogens

423/451

93.8%

Heroin

434/451

96.2%

Hookah

416/451

92.2%

Kratom

40/451

8.9%

Marijuana

442/451

98.0%

Methamphetamine

423/449

94.2%

Methaqualone

59/451

13.1%

OTC Medication Abuse

404/450

89.8%

Salvia

215/451

47.7%

Synthetic Marijuana

346/450

76.9%
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Table 13: Percentage Indicating “Great Harm” for Experimental, Occasional, and Regular Use
of Varied Substances
Drug Name
Alcohol
Experimental Use
Occasional Use
Regular Use
Cigarettes
Experimental Use
Occasional Use
Regular Use
Cocaine
Experimental Use
Occasional Use
Regular Use
Hallucinogens
Experimental Use
Occasional Use
Regular Use
Heroin
Experimental Use
Occasional Use
Regular Use
Hookah
Experimental Use
Occasional Use
Regular Use
Marijuana
Experimental Use
Occasional Use
Regular Use
Methamphetamine
Experimental Use
Occasional Use
Regular Use
OTC Medication
Experimental Abuse
Occasional Abuse
Regular Abuse
Salvia
Experimental Use
Occasional Use
Regular Use

n

%

7
13
199

1.5%
2.9%
44.1%

30
61
353

6.7%
13.5%
78.3%

129
203
405

28.7%
45.1%
90.0%

99
155
316

22.0%
34.4%
70.2%

218
283
418

48.4%
62.9%
92.9%

15
23
97

3.3%
5.1%
21.5%

30
45
115

6.6%
10.0%
25.5%

171
254
404

37.9%
56.3%
89.6%

52
101
309

11.5%
22.4%
68.5%

53
93
202

11.8%
20.6%
44.8%

85

Table 14: Composite Scores on Three Measures of Numeracy: Subjective Numeracy Scale (SNS),
Objective Numeracy Scale (ONS), and Preference for Numerical Information

Measure

M(SD)

Observed Range

Subjective Numeracy Scale (SNS)
(range: 1 – 8)*

4.27(0.90)

1.50 – 6.00

Objective Numeracy Scale (ONS)
(range: 0 – 11)*

6.85 (2.41)

0 – 11

Preference for Numerical Information
(range: 1 – 7)†

3.36 (0.91)

1.05 – 6.05

Note: *higher scores indicate greater numerical ability; †lower scores indicate greater preference
for
numerical information
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Table 15: Perceived likelihood of harm by experimental condition, base-rate information, and
level of use (1 of 2)
______________________________________________________________________________
Base-Rate Presented
Experimental Condition

(80% likelihood of harm)

(80% likelihood of harm)

Drug
Synthetic Marijuana

Kratom

Experimental Use
Base-Rate Info Only

37.8%*

38.9%*

Base-Rate Info Plus
4 Positive Web-Postings

29.5%†

33.6%†

Base-Rate Info Plus
4 Negative Web-Postings

56.7%*†

59.9%*†

Base-Rate Info Only

57.8%*

57.4%*

Base-Rate Info Plus
4 Positive Web-Postings

48.3%†

52.2%†

Base-Rate Info Plus
4 Negative Web-Postings

68.1%*†

73.8%*†

Occasional Use

Note: * difference is statistical at the p < .006 level; † difference is statistical at the p < .006 level
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Table 16: Perceived likelihood of harm by experimental condition, base-rate information, and
level of use (2 of 2)
______________________________________________________________________________
Base-Rate Presented
Experimental Condition

(50% likelihood of harm)

(50%likelihood of harm)

Drug
Synthetic Marijuana

Kratom

Experimental Use
Base-Rate Info Only

39.5%*

33.1%*

Base-Rate Info Plus
4 Positive Web-Postings

32.4%†

26.9%†

Base-Rate Info Plus
4 Negative Web-Postings

58.5%*†

47.3%*†

Base-Rate Info Only

58.0%*

54.2%*

Base-Rate Info Plus
4 Positive Web-Postings

50.8%†

45.2%†

Base-Rate Info Plus
4 Negative Web-Postings

72.6%*†

63.5%*†

Occasional Use

Note: * difference is statistical at the p < .006 level; † difference is statistical at the p < .006 level
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Table 17: Perceived degree of harm by experimental condition, base-rate information, and level
of use (1 of 2)
______________________________________________________________________________
Base-Rate Presented
Experimental Condition

(80% likelihood of harm)

(80%likelihood of harm)

Drug
Synthetic Marijuana

Kratom

Experimental Use
Base-Rate Info Only

3.8*

3.8*

Base-Rate Info Plus
4 Positive Web-Postings

3.4†

2.9†

Base-Rate Info Plus
4 Negative Web-Postings

5.0*†

5.2*†

Base-Rate Info Only

5.2*

5.1*ɵ

Base-Rate Info Plus
4 Positive Web-Postings

4.7†

4.5†ɵ

Base-Rate Info Plus
4 Negative Web Postings

5.8*†

6.1*†

Occasional Use

Note: * difference is statistical at the p < .004 level; † difference is statistical at the p < .004 level
ɵ difference is statistical at the p < .004 level
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Table 18: Perceived degree of harm by experimental condition, base-rate information, and level
of use (2 of 2)
______________________________________________________________________________
Base-Rate Presented
Experimental Condition

(50% likelihood of harm)

(50%likelihood of harm)

Drug
Synthetic Marijuana

Kratom

Experimental Use
Base-Rate Info Only

4.0*

3.3*

Base-Rate Info Plus
4 Positive Web-Postings

3.2†

3.0†

Base-Rate Info Plus
4 Negative Web-Postings

5.2*†

4.5*†

Base-Rate Info Only

5.4*

4.8*ɵ

Base-Rate Info Plus
4 Positive Web-Postings

4.8†

4.3†ɵ

Base-Rate Info Plus
4 Negative Web-Postings

6.0*†

5.5*†

Occasional Use

Note: * difference is statistical at the p < .004 level; † difference is statistical at the p < .004 level
ɵ difference is statistical at the p < .004 level
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Table 19: Intentions to use by experimental condition and base-rate information (1 of 2)
______________________________________________________________________________
Base-Rate Presented
Experimental Condition

(80% likelihood of harm)

(80%likelihood of harm)

Drug
Synthetic Marijuana

Kratom

Base-Rate Info Only

1.1

1.1

Base-Rate Info Plus
4 Positive Web-Postings

1.1

1.1

Base-Rate Info Plus
4 Negative Web-Postings

1.0

1.0
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Table 20: Intentions to use by experimental condition and base-rate information (2 of 2)
______________________________________________________________________________
Base-Rate Presented
Experimental Condition

(50% likelihood of harm)

(50%likelihood of harm)

Drug
Synthetic Marijuana

Kratom

Base-Rate Info Only

1.0

1.1

Base-Rate Info Plus
4 Positive Web-Postings

1.1

1.0

Base-Rate Plus Plus
4 Negative Web-Postings

1.0

1.0
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Table 21: Impact of Numeracy on Likelihood Ratings for Experimental Use of Spice
(Grouping 1)
Variable

B(SE)

95% CI

p

Lower

Upper

Step 1:
ONS scores
(Numeracy measure)

0.23(0.89)

-1.52

2.00

.790

ONS scores
(Numeracy measure)

0.00(0.87)

-1.72

1.73

.996

Experimental Condition

9.41(2.62)

4.23

14.59

.000

Step 2:
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Table 22: Impact of Numeracy on Likelihood Ratings for Experimental Use of Spice
(Grouping 2)
Variable

B(SE)

95% CI
Lower
Upper

p

ONS scores
(Numeracy measure)

1.12(0.89)

-0.62

2.88

.207

ONS scores
(Numeracy measure)

0.93(0.86)

-0.77

2.64

.282

Experimental Condition

9.35(2.46)

4.49

14.22

.000

Step 1:

Step 2:
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Table 23: Impact of Numeracy on Likelihood Ratings for Experimental Use of Kratom
(Grouping 1)
Variable

B(SE)

95% CI

p

Lower

Upper

Step 1:
ONS scores
(Numeracy measure)

0.61(0.82)

-1.00

2.23

.456

ONS scores
(Numeracy measure)

0.44(0.81)

-1.16

2.04

.588

Experimental Condition

6.98(2.43)

2.17

11.78

.005

Step 2:
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Table 24: Impact of Numeracy on Likelihood Ratings for Experimental Use of Kratom
(Grouping 2)
Variable

B(SE)

95% CI
Lower
Upper

p

ONS scores
(Numeracy measure)

1.30(0.94)

-0.56

3.17

.172

ONS scores
(Numeracy measure)

1.09(0.92)

-0.72

2.90

.238

Experimental Condition

10.31(2.62)

5.14

15.48

.000

Step 1:

Step 2:
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Table 25: Correlation Matrix of ONS scores with Deviation Scores (Grouping 1)
Variable

1

2

1. ONS scores

-

2. Likelihood of Harm
For Spice (Experimental Use)

-.04

-

-.08

.38*

3. Likelihood of Harm
For Kratom (Experimental Use)

3

-

Note: * p < .01
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Table 26: Correlation Matrix of ONS scores with Deviation Scores (Grouping 2)
Variable

1

2

4. ONS scores

-

5. Likelihood of Harm
For Spice (Experimental Use)

.03

-

-.12

.175*

6. Likelihood of Harm
For Kratom (Experimental Use)

3

-

Note: * p < .01
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Table 27: Moderation Analyses Examining the Impact of Numeracy on Likelihood Ratings for
Experimental Use of Spice (Grouping 1)
Variable

B (SE)

95% CI
Lower
Upper

p

Synthetic Marijuana
(Lifetime Use)

-18.24(7.19)

-32.41

-4.06

.012

Synthetic Marijuana
(Lifetime Use)

-17.87(6.78)

-31.23

-4.51

.009

Base-Rate Plus Positive
Postings

-8.77(5.01)

-18.65

1.11

.082

Base-Rate Plus Negative
Postings

18.35(5.00)

8.50

28.21

.000

Synthetic Marijuana
(Lifetime Use)

-18.07(6.79)

-31.47

-4.67

.008

Base-Rate Plus Positive
Postings

-9.16(5.06)

-19.15

0.82

.072

Base-Rate Plus Negative
Postings

18.13(5.02)

8.23

28.02

.000

ONS (Numeracy Scores)

0.49(0.84)

-1.16

2.15

.557

Synthetic Marijuana
(Lifetime Use)

-16.50(6.81)

-29.94

-3.06

.016

Base-Rate Plus Positive
Postings

-4.45(14.83)

-33.69

24.78

.764

Base-Rate Plus Negative
Postings

-5.41(14.71)

-34.40

23.58

.713

ONS (Numeracy Scores)

-0.42(1.41)

-3.21

2.35

.762

Base-Rate Plus Positive
Postings by ONS

-0.54(2.02)

-4.53

3.45

.789

Base-Rate Plus Negative
Postings by ONS

3.46(2.06)

-0.60

7.53

.095

Step 1

Step 2

Step 3

Step 4
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Table 28: Moderation Analyses Examining the Impact of Numeracy on Likelihood Ratings for
Experimental Use of Spice (Grouping 2)
Variable

B(SE)

95% CI

p

Lower

Upper

Step 1
Synthetic Marijuana
(Lifetime Use)

-9.67(5.99)

-21.48

2.13

.108

Synthetic Marijuana
(Lifetime Use)

-11.84(5.62)

-22.93

-0.75

.036

Base-Rate Plus Positive
Postings

-7.91(4.74)

-17.26

1.44

.097

Base-Rate Plus Negative
Postings

19.02(4.73)

9.70

28.35

.000

Synthetic Marijuana
(Lifetime Use)

-11.03(5.66)

-22.20

0.14

.053

Base-Rate Plus Positive
Postings

-8.34(4.75)

-17.72

1.03

.081

Base-Rate Plus Negative
Postings

18.70(4.73)

9.36

28.03

.000

ONS (Numeracy Scores)

.097(0.84)

-0.68

2.62

.249

Synthetic Marijuana
(Lifetime Use)

-10.46(5.73)

-21.76

0.82

.069

Base-Rate Plus Positive
Postings

-6.62(14.59)

-35.38

22.13

.650

Base-Rate Plus Negative
Postings

7.31(14.76)

-21.79

36.41

.621

ONS (Numeracy Scores)

0.52(1.40)

-2.24

3.29

.707

Base-Rate Plus Positive
Postings by ONS

-0.20(2.02)

-4.19

3.77

.919

Base-Rate Plus Negative
Postings by ONS

1.67(2.07)

-2.41

5.75

.420

Step 2

Step 3

Step 4
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Table 29: Moderation Analyses Examining the Impact of Numeracy on Likelihood Ratings for
Experimental Use of Kratom (Grouping 1)

Variable

B(SE)

95% CI
Lower
Upper

p

Base-Rate Plus Positive
Postings

-6.23(4.77)

-15.63

3.17

.193

Base-Rate Plus Negative
Postings

14.15(4.75)

4.78

23.52

.003

Base-Rate Plus Positive
Postings

-6.81(4.81)

-16.29

2.67

.159

Base-Rate Plus Negative
Postings

13.83(4.77)

4.43

23.23

.004

ONS (Numeracy Scores)

0.73(0.80)

-0.84

2.30

.363

Base-Rate Plus Positive
Postings

5.75(14.15)

-22.14

33.65

.685

Base-Rate Plus Negative
Postings

3.66(13.96)

-23.85

31.17

.793

ONS (Numeracy Scores)

0.84(1.34)

-1.80

3.48

.530

Base-Rate Plus Positive
Postings by ONS

-1.74(1.93)

-5.55

2.06

.369

Step 1

Step 2

Step 3

Base-Rate Plus Negative
1.46(1.95)
-2.39
5.31
.455
Postings by ONS
Note: lifetime use of kratom was not used in this analysis because no one in the sample reported
lifetime use of kratom
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Table 30: Moderation Analyses Examining the Impact of Numeracy on Likelihood Ratings for
Experimental Use of Kratom (Grouping 2)

Variable

B(SE)

95% CI
Lower
Upper

p

Base-Rate Plus Positive
Postings

-5.29

-15.36

4.77

.301

Base-Rate Plus Negative
Postings

21.00

10.93

31.07

.000

Base-Rate Plus Positive
Postings

-5.96

-16.04

4.12

.245

Base-Rate Plus Negative
Postings

20.56

10.49

30.62

.000

ONS (Numeracy Scores)

1.31

-0.45

3.08

.144

Base-Rate Plus Positive
Postings

-8.32

-39.35

22.70

.598

Base-Rate Plus Negative
Postings

21.13

-10.05

52.32

.183

ONS (Numeracy Scores)

1.22

-1.76

4.22

.419

Base-Rate Plus Positive
Postings by ONS

0.34

-3.95

4.63

.876

Step 1

Step 2

Step 3

Base-Rate Plus Negative
-.07
-4.44
4.29
.972
Postings by ONS
Note: lifetime use of kratom was not used in this analysis because no one in the sample reported
lifetime use of kratom
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Table 31: Inter-correlations among dependent variables

DVs:

1

2

3

4

5

6

7

8

9

10

Spice
1. Perceived Harm
(Exp Use)

-

2. Perceived Harm
(Occ Use)

.81** -

3. Likelihood of
Adverse Event
(Exp Use)

.74** .61** -

4. Likelihood of
Adverse Event
(Occ Use)

.62** .69*

5. Intentions to
Use

-.20** -.26** -.15** -.21** -

.84** -

Kratom
6. Perceived Harm
(Exp Use)

.68** .55** .56** .48** -.10* -

7. Perceived Harm
(Occ Use)

.63** .67** .51** .55** -.10* .83** -

8. Likelihood of
Adverse Event
(Exp Use)

.56** .41** .74** .60** -.03

.74** .61** -

9. Likelihood of
Adverse Event
(Occ Use)

.50** .50** .69** .78** -.06

.63** .71** .80** -

10. Intentions to
Use

-.10* -.10* -.08

-.12** -.18** -.02

-.15** .10*

Note: *significant at the p < .05 level; ** significant at the p < .01 level
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-.14** -

Table 32: Percent of participants scoring 0, 1, 2, 3, and 4 items correct on the M-Scale
Score

Frequency

Percent

Cumulative Percent

0

35

7.7%

7.7%

1

20

4.4%

12.1%

2

46

10.2%

22.3%

3

91

20.1%

42.4%

4

261

57.6%

100.0%

Total

453

100.0%
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Table 33: Percent of participants’ incorrect responses by item and percent of participants’ incorrect
mirror responses by item in the M-Scale

Item #

Frequency

% Incorrect
Response

Frequency

% Incorrect
Mirror Response

1

77

17.1%

9

2.0%

2

84

18.7%

38

8.5%

3

102

22.7%

24

5.4%

4

103

23.0%

11

2.5%

All Incorrect

35

7.7%

3

0.7%
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APPENDIX A: BACKGROUND SURVEY I
1. How old are you (please type number in below)?
______
2. Gender
___ (1) Female
___(2) Male
3. Ethnicity
___African American
___Asian/Asian-American/ Pacific-Islander
___Caucasian/ White (not of Hispanic origin)
___ Hispanic
___Native American
___Other (please specify) _______________________
4. What is you college level?
___Freshman
___Sophomore
___Junior
___Senior
___Not sure
5. What is your approximate grade point average (GPA)? (please type in below)
_______
6. Where did you live the longest when you were growing up (birth to 17 years of age?
___El Paso, TX
___Juarez, Chihuahua
___Las Cruces, NM
___Other (please specify cities and states)
_______________________________
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7. Check the statement that best describes your proficiency to speak both English and
Spanish (check only one)
___I speak only English
___ I speak English fluently, but I do not speak Spanish fluently
___I speak both languages fluently, but my English is much better
___ I speak both languages fluently, but my English is a little better
___I speak both languages with equal fluency
___I speak both languages fluently, but my Spanish is a little better
___I speak both languages fluently, but my Spanish is much better
___I speak Spanish fluently, but I do not speak English fluently
___I speak only Spanish
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APPENDIX B: BACKGROUND SURVEY II
Survey of Past Experiences with Selected Substances (Part I)
Directions: Please indicate your experiences with the following substances by placing a
checkmark next to the appropriate space.

Never tried

1.
2.
3.
4.

Alcohol
(such as beer, liquor, wine)
Tobacco (such as cigarettes,
dip)
Cocaine (known as coke)

5.

Hallucinogens (such as
“magic mushrooms”)
Heroin

6.

Hookah tobacco

7.

Kratom

8.

Marijuana
(known as pot, weed)
9. Methamphetamine
(known as“ice” or “meth”)
10. Methaqualone
(known as “quaaludes”)
11. Abused over-the-counter
(OTC) medication
12. Salvia
13. Synthetic Marijuana
(such as “Spice”, “K2”)
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Tried and
never
had a bad
experience

Tried and
sometimes
had a bad
experience

Tried and
often had a
bad
experience

APPENDIX B: BACKGROUND SURVEY II (CONTINUED)

Directions: Please indicate your experiences with the following substances by placing a
checkmark next to the appropriate space.
Never tried

1.
2.
3.
4.

Alcohol
(such as beer, liquor, wine)
Tobacco (such as
cigarettes, dip)
Cocaine (known as coke)

5.

Hallucinogens (such as
“magic mushrooms”)
Heroin

6.

Hookah tobacco

7.

Kratom

8.

Marijuana
(known as pot, weed)
9. Methamphetamine
(known as“ice” or “meth”)
10. Methaqualone
(known as “quaaludes”)
11. Abused over-the-counter
(OTC) medication
12. Salvia
13. Synthetic Marijuana
(such as “Spice”, “K2”)
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Tried and
never
had a good
experience

Tried and
sometimes
had a good
experience

Tried and
often had a
good
experience

APPENDIX B: BACKGROUND SURVEY II (CONTINUED)
Survey of Past Experiences with Selected Substances (Part II)
This section deals with alcohol and various other substances. There is a lot of talk these days
about these substances, but very little accurate information. Therefore, we still have a lot to
learn about the actual experiences and attitudes of people your age. Please answer all questions
honestly.
I. On how many occasions (if any) have you had any alcoholic beverages (such as beer,
wine, liquor) to drink—more than just a few sips…
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
II. On how many occasions (if any) have you smoked cigarettes…
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
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(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
III. On how many occasions (if any) have you used cocaine (known as coke)…
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
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(5)
(6)
(7)
(8)

10-19 times
20-29 times
30-39 times
40 or more times

IV. On how many occasions (if any) have you used hallucinogens (such as “magic
mushrooms” )…
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
V. On how many occasions (if any) have you used heroin
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
112

(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
VI. On how many occasions (if any) have you used hookah tobacco
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
113

VII. On how many occasions (if any) have you used the herb kratom…
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
VIII. On how many occasions (if any) have you used marijuana (known as pot, weed) or
hashish (known as hash or hash oil)…
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
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(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
IX. On how many occasions (if any) have you used methamphetamine (known as “ice” or
“meth”)…
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
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X. On how many occasions (if any) have you used methaqualone (known as “quaaludes”)…
… in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
XI. On how many occasions (if any) have you used over-the-counter (OTC) medications
(such as Robitussin, Coricidin) for the purposes of getting buzzed or high…
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
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(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
XII. On how many occasions (if any) have you used the herb salvia…
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
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XIII. On how many occasions (if any) have you used synthetic marijuana (known as
“Spice”, “K2”)…
…in your lifetime?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 12 months?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
…during the last 30 days?
(1) Never
(2) 1-2 times
(3) 3-5 times
(4) 6-9 times
(5) 10-19 times
(6) 20-29 times
(7) 30-39 times
(8) 40 or more times
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APPENDIX C: FAMILIARITY WITH VARIED SUBSTANCES

Survey of Familiarity with Varied Substances

1. Before taking part in this study had you heard of any of the following substances?
(please circle your answer)
a. Alcohol (such as beer, liquor, wine)

YES

/

NO

b. Tobacco (such as cigarettes, dip)

YES

/

NO

c. Cocaine (known as coke)

YES

/

NO

d. Hallucinogens (such as “magic mushrooms”)

YES

/

NO

e. Heroin

YES

/

NO

f. Hookah Tobacco

YES

/

NO

g. Kratom

YES

/

NO

h. Marijuana (known as pot, weed)

YES

/

NO

i. Methamphetamine (known as “ice” or “meth”)

YES

/

NO

j. Methaqualone (known as “quaaludes”)

YES

/

NO

k.

Salvia

YES

/

NO

l.

Synthetic Marijuana (known as “Spice” , “K2”)

YES

/

NO

YES

/

NO

m. The use of over-the counter (OTC)
medication for the purposes of getting
“buzzed” or high
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APPENDIX D: PERCEIVED HARMFULNESS OF VARIED SUBSTANCES
Opinion Survey
This section deals with alcohol and various other substances. There is a lot of talk these days
about these substances, but very little accurate information. Therefore, we still have a lot to
learn about the actual experiences and attitudes of people your age. Please answer all questions
honestly.

Directions: Please answer the following questions by circling your answer below.
(Substances are listed in alphabetical order)

1. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use alcohol
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use alcohol
OCCASIONALLY?

1

2

3

4

5

6

7

…Use alcohol
REGULARLY?

1

2

3

4

5

6

7

2. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use cigarettes
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use cigarettes
OCCASIONALLY?

1

2

3

4

5

6

7

…Use cigarettes
REGULARLY?

1

2

3

4

5

6

7
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3. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use cocaine
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use cocaine
OCCASIONALLY?

1

2

3

4

5

6

7

…Use cocaine
REGULARLY?

1

2

3

4

5

6

7

4. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use hallucinogens
(such as “magic mushrooms”)
ONCE OR TWICE
just to see what it is like?
1

2

3

4

5

6

7

…Use hallucinogens
(such as “magic mushrooms”)
OCCASIONALLY?
1

2

3

4

5

6

7

…Use hallucinogens
(such as “magic mushrooms”)
REGULARLY?
1

2

3

4

5

6

7

5. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use heroin
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use heroin
OCCASIONALLY?

1

2

3

4

5

6

7

…Use heroin
REGULARLY?

1

2

3

4

5

6

7
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6. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use hookah tobacco
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use hookah tobacco
OCCASIONALLY?

1

2

3

4

5

6

7

…Use hookah tobacco
REGULARLY?

1

2

3

4

5

6

7

7. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use marijuana
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use marijuana
OCCASIONALLY?

1

2

3

4

5

6

7

…Use marijuana
REGULARLY?

1

2

3

4

5

6

7

8. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use methamphetamine
(known as “ice” or “meth”)
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use methamphetamine
(known as “ice” or “meth”)
OCCASIONALLY?

1

2

3

4

5

6

7

…Use methamphetamine
(known as “ice” or “meth”)
REGULARLY?

1

2

3

4

5

6

7
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9. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm
…Use over-the-counter
medication
ONCE OR TWICE
for the purpose of
getting buzzed or
high just to see what
it is like?
…Use over-the-counter
medication
OCCASIONALLY
for the purpose of
getting buzzed or
high?
…Use over-the-counter
medication
REGULARLY
for the purpose of
getting buzzed or
high?

Moderate
Harm

Great
Harm

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

10. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use the herb salvia
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use the herb salvia
OCCASIONALLY?

1

2

3

4

5

6

7

…Use the herb salvia
REGULARLY?

1

2

3

4

5

6

7
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APPENDIX E: PREFERENCE FOR NUMERICAL INFORMATION

Numerical Information Opinion Survey (Part I)
1. I enjoy work that requires the use of numbers.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

2. I think quantitative information is difficult to understand.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

3. I find it satisfying to solve day-to-day problems involving numbers.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

4. Numerical information is very useful in everyday life.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

5. I prefer not to pay attention to information involving numbers.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

6. I think more information should be available in numerical form.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

7. I don’t like to think about issues involving numbers.
1
Strongly
Agree

2

3

4

5

6
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7
Strongly
Disagree

8. Numbers are not necessary most situations.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

9. Thinking is enjoyable when it does not involve quantitative information.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

10. I like to make calculations using numerical information.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

11. Quantitative information is vital for accurate decisions.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

12. I enjoy thinking about issues that do not involve numerical information.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

13. Understanding numbers is as important in daily life as reading or writing.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

14. I easily lose interest in graphs, percentages, and other quantitative information.
1
Strongly
Agree

2

3

4

5

6
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7
Strongly
Disagree

15. I don’t find numerical information to be relevant for most situations.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

16. I think it is important to learn and use numerical information to make well-informed
decisions.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

6

7
Strongly
Disagree

17. Numbers are redundant for most situations.
1
Strongly
Agree

2

3

4

5

18. It is a waste of time to learn information containing a lot of numbers.
1
Strongly
Agree

2

3

4

5

6

7
Strongly
Disagree

5

6

7
Strongly
Disagree

19. I like to go over numbers in my mind.
1
Strongly
Agree

2

3

4

20. It helps me to think if I put down information as numbers.
1
Strongly
Agree

2

3

4

5

6
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7
Strongly
Disagree

APPENDIX F: SUBJECTIVE NUMERACY SCALE (SNS)
1. How good are you at working with fractions?
1
Not at all
Good

2

3

4

5

6
Extremely
Good

5

6
Extremely
Good

5

6
Extremely
Good

2. How good are you at working with percentages?
1
Not at all
Good

2

3

4

3. How good are you at calculating a 15% tip?
1
Not at all
Good

2

3

4

4. How good are you at figuring out how much a shirt will cost if it is 25% off?
1
Not at all
Good

2

3

4

5

6
Extremely
Good

5. When reading the newspaper, how helpful do you find table and graphs that are part of a
story?
1
Not at all
Helpful

2

3

4

5

6
Extremely
Helpful

6. When people tell you the chance of something happening, do you prefer that they use words
(“it rarely happens”) or numbers (“there’s a 1% chance”)?
1
2
Always Prefer
Words

3

4

5
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6
Always Prefer
Numbers

7. When you hear the weather forecast, do you prefer predictions using percentages (e.g., “there
will be a 20% chance of rain today”) or predictions using only words (e.g., “there’s a small
chance of rain today”)?
1
2
Always Prefer
Percentages

3

4

5

6
Always Prefer
Words

8. How often do you find numerical information to be useful?
1
Never

2

3

4

5
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6
Very Often

APPENDIX G: OBJECTIVE NUMERACY SCALE (ONS)

1. Imagine that we have a fair, 6-sided die (for example, from a board game or casino craps
table). Imagine that we now roll it 1000 times. Out of 1000 rolls, how many times do
you think the die would come up even (numbers 2, 4, or 6)?
2. In the Big Bucks Lottery, the chances of winning a $10.00 prize is 1%. What is your best
guess about how many people would win a $10.00 prize if 1000 people each buy a single
ticket to Big Bucks?
3. In the Acme Publishing Sweepstakes, the chance of winning a car is 1 in 1000. What
percentage of tickets to Acme Publishing Sweepstakes win a car?
4. Which if the following numbers represent the biggest risk of getting a disease?
___ 1 in 100
___1 in 1000
___1 in 10
5. Which of the following numbers represents the biggest risk of getting a disease?
___1%
___10%
___5%
6. If a person A’s risk of getting a disease is 1% in 10 years, and person B’s risk is double
that of A’s, what is B’s risk?
7. If a person A’s chance of getting a disease is 1 in 100 in 10 years, and person B’s risk is
double that of A’s, what is B’s risk?
8. If the chance of getting a disease is 10%, how many people of 100 would get the disease?
9. If a chance of getting a disease is 10%, how many people out of 1000 would be expected
to get the disease?
10. If the chance of getting a disease is 20 out of 100, this would be the same as having a
___% chance of getting the disease?
11. The chance of getting a viral infection is 0.0005. Out of 10,000 people, about how many
of them are expected to get infected?
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APPENDIX H: BRIEF SENSATION SEEKING SCALE (BSSS)
1. I would like to explore strange places.
1
Strongly
Disagree

2
Disagree

3
Neither Disagree
nor Agree

4
Agree

5
Strongly
Agree

3
Neither Disagree
nor Agree

4
Agree

5
Strongly
Agree

3
Neither Disagree
nor Agree

4
Agree

5
Strongly
Agree

3
Neither Disagree
nor Agree

4
Agree

5
Strongly
Agree

2. I get restless when I spend too much time at home.
1
Strongly
Disagree

2
Disagree

3. I like to do frightening things.
1
Strongly
Disagree

2
Disagree

4. I like wild parties.
1
Strongly
Disagree

2
Disagree

5. I would like to take off on a trip with no pre-planned route or timetables.
1
Strongly
Disagree

2
Disagree

3
Neither Disagree
nor Agree

4
Agree

5
Strongly
Agree

4
Agree

5
Strongly
Agree

6. I prefer friends who are excitingly unpredictable
1
Strongly
Disagree

2
Disagree

3
Neither Disagree
nor Agree
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7. I would like to try bungee jumping.
1
Strongly
Disagree

2
Disagree

3
Neither Disagree
nor Agree

4
Agree

5
Strongly
Agree

8. I would love to have new and exciting experiences, even if they are illegal.
1
Strongly
Disagree

2
Disagree

3
Neither Disagree
nor Agree
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4
Agree

5
Strongly
Agree

APPENDIX I: M-SCALE

Short Story Exercise
1. Richard is an avid skier and spends 90% of his vacations skiing. Today he has plane
tickets to Aspen, Colorado and has been looking forward to this weekend trip for months.
Unfortunately, Richard had a bad accident and both of his legs are broken. What is the
probability that Richard will go skiing this weekend? ___ %

2. In Little Rock, Arkansas only 10% of the High School soccer referees are women. Sam
has been a High School soccer referee for three years. Sam will not be refereeing this
year because Sam is pregnant. What is the probability that Sam is a woman? ___ %

3. The town of Springfield has a nice botanical garden. What makes the garden unique is
that it has dozens of wind chimes that make beautiful music in the soft summer breeze.
About 70% of visitors to the garden report that they come to listen to the wind chimes.
Mrs. Addison, who happens to be deaf, is visiting the botanical garden today. What is the
probability that Mrs. Addison is visiting to listen to the wind chimes? __%
4. Jessica is on her lunch break. She doesn’t have much time so she decided to pop into
McDonald’s for a quick lunch. About 80% of McDonald’s customers order some kind of
hamburger. However, Jessica is a vegetarian. What is the probability that Jessica will
order a hamburger? ___ %
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APPENDIX J: BASE-RATE ONLY CONDITION

Web Discussion Forum Task #1
Imagine you posted a question on an online discussion forum about the effects of synthetic
marijuana (such as “Spice,” “K2”), a drug you recently heard about. You receive the
following reply:
“Spice is a type of artificial or ‘synthetic’ marijuana and it is commonly sold as ‘incense.’ Spice
contains artificial chemicals that are much stronger than the chemicals found in traditional
marijuana. The American Medical Association recently studied 500 young adults, ages 18 – 25,
who reported using Spice. Approximately, 400 of these young adults experienced negative
reactions such as paranoia, hallucinations, and dangerous increases in blood pressure.”
– Alexander Hoffstead, M.D., Senior Scientist, Johns Hopkins University
1. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use synthetic marijuana
(such as “Spice”, “K2”)
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use synthetic marijuana
(such as “Spice”, “K2”)
OCCASIONALLY?

1

2

3

4

5

6

7

…Use synthetic marijuana
(such as “Spice”, “K2”)
REGULARLY?

1

2

3

4

5

6

7

2. In your opinion, using a scale from 0 – 100%, how likely are you to harm yourself (physically
and in other ways) if you…
(Please write numbers in below. “0” means “no chance” and “100” means “definitely”)
…Use synthetic marijuana
(such as “Spice”, “K2”)
ONCE OR TWICE
just to see what it is like?

____%

…Use synthetic marijuana
(such as “Spice”, “K2”)
OCCASIONALLY?

____%
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…Use synthetic marijuana
(such as “Spice”, “K2”)
REGULARLY?

____%

3. During the next 12 months how many times do you think you will use synthetic marijuana
(such as “Spice,” “K2”) in the next 12 months?
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)

Never
1-2 times
3-5 times
6-9 times
10-19 times
20-29 times
30-39 times
40 or more times

134

Web Discussion Forum Task #2

Imagine you posted a question on an online discussion forum about the effects of the herb
Kratom, a drug you recently heard about. You receive the following reply:
“Kratom is a plant native to Thailand and Malaysia and has opiate-like (analgesic) properties.
The American Medical Association recently studied 1000 young adults, ages 18 – 25, who
reported using kratom. Approximately, 500 of these young adults experienced negative symptoms
such as nausea, vomiting, and difficulty breathing.”
-Timothy Shulgin, M.D., Senior Scientist, Johns Hopkins University
1. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use the herb kratom
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use the herb kratom
OCCASIONALLY?

1

2

3

4

5

6

7

…Use the herb kratom
REGULARLY?

1

2

3

4

5

6

7

2. In your opinion, on a scale from 0 – 100%, how likely are you to harm yourself (physically
and in other ways) if you…
(Please write numbers in below. “0” means “no chance” and “100” means “definitely”)
…Use the herb kratom
ONCE OR TWICE
just to see what it is like?

____%

…Use the herb kratom
OCCASIONALLY?

____%

…Use the herb kratom
REGULARLY?

____%
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3. During the next 12 months, how many times do you think you will use the herb kratom the
next 12 months?
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)

Never
1-2 times
3-5 times
6-9 times
10-19 times
20-29 times
30-39 times
40 or more times
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APPENDIX K: BASE-RATE PLUS POSITIVE WEB-POSTINGS CONDITION

Web Discussion Forum Task #1
Imagine you posted a question on an online discussion forum about the effects of synthetic
marijuana (such as “Spice,” “K2”), a drug you recently heard about. You receive the
following replies that all deal with experiences that result from using synthetic marijuana
(such as “Spice,” “K2”). Some of the replies describe positive experiences while others
describe negative experiences.
(Please read each reply carefully)

Web-Posting #1
“Spice is a type of artificial or ‘synthetic’ marijuana and it is commonly sold as ‘incense.’ Spice
contains artificial chemicals that are much stronger than the chemicals found in traditional
marijuana. The American Medical Association recently studied 1000 young adults, ages 18 –
25, who reported using Spice. Approximately, 800 of these young adults experienced negative
reactions such as paranoia, hallucinations, and dangerous increases in blood pressure.”
– Alexander Hoffstead, M.D., Senior Scientist, Johns Hopkins University
Web-Posting #2
“My experience with Spice has changed my life in such a positive way. I feel like I don’t know
what I ever did without it. This relaxing substance has become my escape from a very stressful
life. I work a very fast- faced job that is very taxing on my body. This little bag brings me
indescribable joy. It does not seem addictive, and it doesn’t really bother me if I run out for a
couple weeks. It’s like cold lemonade on a hot summer day.”
Web-Posting #3
“I have tried Spice and it is by far the most potent and marijuana-like high I have ever
experienced! It was so good in fact that I quit smoking bud! The effects come on in 10 minutes
and are intense waves of relaxation, feeling care-free, munchies, red eyes, etc. All the same side
effects of marijuana besides paranoia. Overall I can’t say how happy I am with this. Even though
it contains synthetic cannabinoids, it doesn’t bother me. No hangover or tiredness the next day
either which is great since weed tended to make me feel very lazy and unmotivated even the next
morning. All in all I give this product two thumbs up!”
Web-Posting #4
I had gone down to a head shop close by my house. I exited the shop with ‘Spice’ in hand, hoping
to simply later get high and go for a walk. I waited till my parents were in bed, and then I slipped
outside on my patio, and lighted up. Not much occurred right away, but then very quickly I
began to feel light-headed. Here’s where it gets weird. I don’t exactly remember the course of
events, but I had some incredibly uncomfortable mental visuals and experiences. I was being
transported through different realities. It was horrible. I went progressively into worse realities,
at one point I went into a reality that I had originally thought was where people went when they
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died. It was constant struggle, constant discomfort. When I tried to relax it forced me back, and
there was no release, no bringing down of intensity. I decided to go inside and lie down and
make it seem like I had simply fallen asleep in front of the TV. But then I vomited on my couch.
After some waiting, lights began to flip on, and my mom came into the sunroom. She asked what
was going on. I said I felt sick. “Yea me too,” she said. “Not like this,” I thought. She watched
and stood there as I vomited some more. It seemed like time was frozen, she wouldn’t move. She
asked what I thought it could be. “Food poisoning?” she asked. “No, I don’t think so mom.” I
vomited again. What can I say about this? It was the worst experience of my life. . I honestly felt
like I was going to die that night. I had always wanted to see if I could experience another world.
I experienced another world. I was brought to different realities, places that fucked up my view
of the world. A disconnection filled with feelings that could never be felt in the real world. A total
disorientation and confusion. And the vomiting. And the spinning. I couldn’t escape. The whole
experience lasted several hours. I may have cried for brief moments of time. It was horror.
Web-Posting #5
“Over the past three or so months ‘Spice’ has become exceedingly popular at my school. So
after getting busted by my parents for weed for the 2nd time I decided I’d quit. But after hearing
about this stuff and fearing a drug test, I decided I would see what it is all about. I went to our
local head shop and bought some ‘Spice’. We smoked it in the backyard. I notice incredible
marijuana-like high setting in, heightened appreciation for auditory stimuli-the birds and bugs
outside created an extraordinary music like symphony of sound. As we walk back to our car we
see a big knotted tree, the bark of which begins to shift into different shapes and swirls around.
We walk up to the tree, hug it, and talk to it for upwards of 15 minutes. I’ve felt a body high
similar to what I feel on marijuana. People I’ve talked to weren’t kidding when they said this
was stronger than weed. For a comparison I would multiply the weed high by about 4. Overall it
was a very enjoyable experience.”
Web-Posting #6
“I quit smoking weed about a year and a half ago. I decided that pot was interfering with my life.
When I stumbled upon Spice on the internet, I was curious to see if it lived up to the hype so I got
Spice off the internet and had it delivered 4 days later. I read that it contained synthetic
marijuana-like chemicals, but was legal and did not show up in a drug test, so I was eager to try
it. About 10 minutes in, I started thinking that I had been ripped off and that this stuff was
complete bullshit. Until all of a sudden, I start feeling this warmth over my body, creeping over
my back, then my legs start to buzz with energy. I had a very intense body high and I was nothing
less than impressed. My depth perception became distorted and I started to stare into nothing for
a while. Everything felt very cloudy and it felt like a dream. I was really high for about 2 hours,
just completely relaxed and in a trance state, and came down for about another 3 or 4 hours. The
effects I got from Spice were almost 100% identical to some good marijuana; I got cottonmouth,
red-eyed, time distortion and bad munchies. Music sounded amazing. I was able to fall asleep on
it no problem.”
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1. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use synthetic marijuana
(such as “Spice”, “K2”)
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use synthetic marijuana
(such as “Spice”, “K2”)
OCCASIONALLY?

1

2

3

4

5

6

7

…Use synthetic marijuana
(such as “Spice”, “K2”)
REGULARLY?

1

2

3

4

5

6

7

2. In your opinion, on a scale from 0 – 100%, how likely are you to harm yourself (physically
and in other ways) if you…
(Please write numbers in below. “0” means “no chance” and “100” means “definitely”)
…Use synthetic marijuana
(such as “Spice”, “K2”)
ONCE OR TWICE
just to see what it is like?

____%

…Use synthetic marijuana
(such as “Spice”, “K2”)
OCCASIONALLY?

____%

…Use synthetic marijuana
(such as “Spice”, “K2”)
REGULARLY?

____%

3. During the next 12 months how many times do you think you will use synthetic marijuana
(such as “Spice,” “K2”) in the next 12 months?
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)

Never
1-2 times
3-5 times
6-9 times
10-19 times
20-29 times
30-39 times
40 or more times
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Web Discussion Forum Task #2
Imagine you posted a question on an online discussion forum about the effects of the herb
kratom, a drug you recently heard about. You receive the following replies that all deal
with experiences that result from kratom. Some of the replies describe positive experiences
while others describe negative experiences.
(Please read each reply carefully)
Web-Posting #1
“Kratom is a plant native to Thailand and Malaysia and has opiate-like (analgesic) properties.
The American Medical Association recently studied 1000 young adults, ages 18 – 25, who
reported using kratom. Approximately, 500 of these young adults experienced negative symptoms
such as nausea, vomiting, and difficulty breathing.”
-Timothy Shulgin, M.D., Senior Scientist, Johns Hopkins University
Web-Posting #1
“After trying Kratom, I felt very relaxed in my body, but felt mentally active. It was a good
feeling, and since I am usually very antsy and restless, the relaxation was a blessing for me. I
also felt mentally at ease as if everything were right in the world. Overall, I would recommend
this for total relaxation and ease of anxiety without being overwhelmingly mind altering.”
Web-Posting #2
“I was very surprised the first time I tried Kratom. This feeling is characterized by a strong
sense of well-being, social enhancement, empathy, surface euphoria, as well as a very warm,
deep connected feeling. Overall, it is a good pain reliever. It motivates the mind and body for
work and study and gives me a profound sense of well-being. It has without a doubt become one
of my favorite herbs.”
Web-Posting #3
I was hesitant submitting this story due to privacy concerns. About half an hour after trying
some of the extract I was overwhelmed with a sense I needed to lay down. Next thing I know, my
friend is standing over me on the kitchen floor trying to wake me up. It turns out I had convulsed
at the table and passed out. I was weak, disoriented and had trouble speaking. After laying there
for about five minutes, unable physically to do much, my friend tried to sit me up. I immediately
passed out again. At this point my friend took my pulse. I was running at between 35-40 beats a
minute, which is exceptionally low from my understanding. After a half hour I was able to stand
up and walk to the bathroom. Both he and I thought I was going to die. This was not fun or
enlightening.
Web-Posting #4
“I have noticed that Kratom has wonderful anti-anxiety, anti-depressant, painkilling, diuretic,
prolonged sexual intercourse, and even nasal decongestant qualities. It is my cure all. I have
noticed no detrimental effects from drinking it, and at any quantity. My body seems to tell me
that I have had all I need, once I have reached an awesome plateau of good feelings.”
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Web Posting #5
“Wow! What to say about Kratom other than I found it an excellent tool for self-healing. Kratom
(for me) simply showed me myself, like looking into a mirror and showing me my true Reflection.
There were no tassels or glittery sparks, just honest introspection. I don’t consider it addictive. I
think Kratom is something I’ll take maybe twice a year, alone, as a sort of periodic self-healing
session. I had mild nausea which soon subsided. I spent the remainder of the night glowing with
the energy I had gained working through my tensions. I felt very free, happy, and euphoric. All I
can say is that Kratom is a real hidden gem. The kind of substance no-one really talks about, but
it’s nothing less because of it.”
1. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use the herb kratom
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use the herb kratom
OCCASIONALLY?

1

2

3

4

5

6

7

…Use the herb kratom
REGULARLY?

1

2

3

4

5

6

7

2. In your opinion, on a scale from 0 – 100%, how likely are you to harm yourself (physically
and in other ways) if you…
(Please write numbers in below. “0” means “no chance” and “100” means “definitely”)
…Use the herb kratom
ONCE OR TWICE
just to see what it is like?

____%

…Use the herb kratom
OCCASIONALLY?

____%

…Use the herb kratom
REGULARLY?

____%
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3. During the next 12 months, how many times do you think you will use the herb kratom the
next 12 months?
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)

Never
1-2 times
3-5 times
6-9 times
10-19 times
20-29 times
30-39 times
40 or more times

142

APPENDIX L: BASE-RATE PLUS NEGATIVE WEB-POSTINGS CONDITION

Web Discussion Forum Task #1

Imagine you posted a question on an online discussion forum about the effects of synthetic
marijuana (such as “Spice,” “K2”), a drug you recently heard about. You receive the
following replies that all deal with experiences that result from using synthetic marijuana
(such as “Spice,” “K2”). Some of the replies describe positive experiences while others
describe negative experiences.
(Please read each reply carefully)

Web-Posting # 1
“Spice is a type of artificial or ‘synthetic’ marijuana and it is commonly sold as ‘incense.’ Spice
contains artificial chemicals that are much stronger than the chemicals found in traditional
marijuana. The American Medical Association recently studied 1000 young adults, ages 18 –
25, who reported using Spice. Approximately, 800 of these young adults experienced negative
reactions such as paranoia, hallucinations, and dangerous increases in blood pressure.”
– Alexander Hoffstead, M.D., Senior Scientist, Johns Hopkins University
Web-Posting #2
“Never again. It’s been less than 12 hours since I smoked three or four hits of Spice and I can
confidently say that I have never been through a worse experience in my life. I am no newbie
when it comes to holding yourself together on psychedelics. My mental fortitude is second to very
few. I’m a strong person, so when I tell you I will NEVER touch this again, you should
understand how FUCKED UP this stuff is. My journey began at the head shop last night. I’m
looking for employment right now, so I’m trying to lay off smoking for obvious reasons. I smoked
the old chemical form of Spice before it was made illegal, so I was surprised when the owner of
the head shop recommended the new chemical form of synthetic marijuana they created to
replace the old (so it would stay legal). I picked up a gram of Spice. My roommate and I got
home and immediately packed a bowl. I am so glad we stopped there. This wasn’t like weed.
This was a new, awful experience. My head was completely disconnected from my body. I
couldn’t feel my extremities. I felt like each breath wasn’t enough. I started breathing as deeply
as I could, but it never seemed like I enough. I was in a state of extreme terror. I couldn’t focus
on anything too long, and I was dizzy as hell. I could only hope my roommate wasn’t
experiencing the same thing. I thought I was going to die. I have never felt like that in all my
years of tripping and smoking. Thankfully, after about two hours, I came down enough to relax a
bit, but a slight feeling of anxiety stayed with me throughout the night. I took my hits at about
9:15 or 9:30pm. By 11:30pm I was alright, but I didn’t fall asleep till after 2 o’ clock in the
morning. I will NEVER try this substance again.”
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Web-Posting #3
“I had gone down to a head shop close by my house, I exited the shop with Spice in hand, hoping
to simply later get high and go for a walk. I waited till my parents were in bed, and then I slipped
outside on my patio, and lighted up. Not much occurred right away, but then very quickly I
began to feel light-headed. Here’s where it gets weird. I don’t exactly remember the course of
events, but I had some incredibly uncomfortable mental visuals and experiences. I was being
transported through different realities. It was horrible. I went progressively into worse realities,
at one point I went into a reality that I had originally thought was where people went when they
died. It was constant struggle, constant discomfort. When I tried to relax it forced me back, and
there was no release, no bringing down of intensity. I decided to go inside and lie down and
make it seem like I had simply fallen asleep in front of the TV. But then I vomited on my couch.
After some waiting, lights began to flip on, and my mom came into the sunroom. She asked what
was going on. I said I felt sick. “Yea me too,” she said. “Not like this,” I thought. She watched
and stood there as I vomited some more. It seemed like time was frozen, she wouldn’t move. She
asked what I thought it could be. “Food poisoning?” she asked. “No, I don’t think so mom.” I
vomited again. What can I say about this? It was the worst experience of my life. I honestly felt
like I was going to die that night. I had always wanted to see if I could experience another world.
I experienced another world. I was brought to different realities, places that fucked up my view
of the world. A disconnection filled with feelings that could never be felt in the real world. A total
disorientation and confusion. And the vomiting. And the spinning. I couldn’t escape. The whole
experience lasted several hours. I may have cried for brief moments of time. It was horror.”
Web-Posting #4
My experience with Spice has changed my life in such a positive way. I feel like I don’t know
what I ever did without it. This relaxing substance has become my escape from a very stressful
life. I work a very fast- faced job that is very taxing on my body. This little bag brings me
indescribable joy. It does not seem addictive, and it doesn’t really bother me if I run out for a
couple weeks. It’s like cold lemonade on a hot summer day.
Web-Posting #5
“I began the day completely sober, and was offered ‘’Spice’ by a friend, an herbal head shop
blend which, I believe, contains synthetic cannabinoids. I did not expect to react in what I can
only describe as a seizure. Within two minutes of smoking it, I began to feel that familiar stoned
feeling and decide to go for a walk alone. The experience soon became unpleasant. Confused, I
walked to a bus stop intending to head home. I sat on the bench, at which point my arms and legs
began shaking. I struggled to stand up to take bus fare out of my pocket, before realizing I was
unable to move my hands with coordination. My legs then gave out and I fell back onto the
bench, hitting my head off the glass backing. At this point the shaking was uncontrollable. Within
moments, I was convulsing uncontrollably and hit my head repeatedly off the glass behind me. I
was then unable to open my eyes, and fell to the ground, hitting my head again off the bench. On
the ground, I was convulsing uncontrollably and hitting my head repeatedly. After what seemed
like an eternity, the ambulance arrived, along with a fire truck, and squad car. The ambulance
crew lifted me to my feet, and I was once again able to open my eyes, though my vision was
heavily distorted. Once in the ambulance, I sat down and once again my arms and legs began
convulsing. I was put on an oxygen mask, which I then realized I desperately needed. Upon
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arrival at the hospital, I was amazed to be able to walk unassisted. I was admitted to hospital at
roughly 6pm, and must have smoked the substance around 4 or 5pm.”
Web-Posting #6
“I started to feel the high come on, and as soon as I did, I had realized I was the highest I had
ever been in my whole entire life and that I completely fucked up. Feeling my heart going a
million miles an hour, I thought I was going to have a heart attack and die right where I was
sitting on the bank of the lake. My vision started to vibrate and blur and everything seemed 3D to
me. About 20 minutes later I was tripping balls. I was trying to hold on to a thin thread of life
that I felt was being pulled away from my body. An extreme surge of pain shot up my left
Jugular vein and everything turned white. I thought I had just died at that exact moment. Ten
seconds later everything came back to me. I went home after a few hours and decided that I
never wanted to do it again because I knew that if I did do it again . .... I wouldn’t survive it the
next time. I got rid of my piece, lighter, and eye drops and planned to never do it again.”
1. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use synthetic marijuana
(such as “Spice”, “K2”)
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use synthetic marijuana
(such as “Spice”, “K2”)
OCCASIONALLY?

1

2

3

4

5

6

7

…Use synthetic marijuana
(such as “Spice”, “K2”)
REGULARLY?

1

2

3

4

5

6

7

2. In your opinion, on a scale from 0 – 100%, how likely are you to harm yourself (physically
and in other ways) if you…
(Please write numbers in below. “0” means “no chance” and “100” means “definitely”)
…Use synthetic marijuana
(such as “Spice”, “K2”)
ONCE OR TWICE
just to see what it is like?

____%

…Use synthetic marijuana
(such as “Spice”, “K2”)
OCCASIONALLY?

____%
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…Use synthetic marijuana
(such as “Spice”, “K2”)
REGULARLY?

____%

3. During the next 12 months how many times do you think you will use synthetic marijuana
(such as “Spice,” “K2”) in the next 12 months?
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)

Never
1-2 times
3-5 times
6-9 times
10-19 times
20-29 times
30-39 times
40 or more times
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Web Discussion Forum Task #2
Imagine you posted a question on an online discussion forum about the effects of the herb
kratom, a drug you recently heard about. You receive the following replies that all deal
with experiences that result from kratom. Some of the replies describe positive experiences
while others describe negative experiences.
(Please read each reply carefully)

Web-Posting #1
“Kratom is a plant to Thailand and Malaysia and has opiate-like (analgesic) properties. The
American Medical Association recently studied 1000 young adults, ages 18 – 25, who reported
using the herb kratom. Appoximately, 500 of these young adults experienced negative symptoms
such as nausea, vomiting, and difficulty breathing.”
-Timothy Shulgin, M.D., Senior Scientist, Johns Hopkins University
Web-Posting #2
“After taking kratom I was put in the hospital after my parents noticed my eyes were yellow. The
whole thing seems to start the day after taking kratom. My mom called the ambulance, as I was
suffering from chest pain, itchy skin, and shortness of breath. After doing some tests they found
my liver enzymes were sky high. I was released from the hospital that night. Since then, I’ve been
in and out of the hospital for the last 5 days having tests done. I can’t blame the kratom directly,
but it seems it was the only thing I did different.”
Web-Posting #3
“In mid-October I began using kratom. For the next two weeks, I used it almost daily. The effects
were subtle and positive. It wasn’t as obvious as opiates, but I noticed that my workdays were
much more enjoyable, and my boss much more tolerable. On Halloween weekend I suddenly
became very ill and immediately stopped use. I experienced fatigue and an extreme loss of
appetite, along with a sharp pain in my abdomen. I could not keep food down for the first week
or so. I became extremely jaundiced and, as is common with jaundice, my entire body was itchy.
I was taken to the hospital and the diagnosis of hepatitis was made as my liver enzymes were
elevated to ten times what is considered normal. I have seen specialists about this illness and a
cause (other than kratom) cannot be found. I believe, though I cannot prove, that kratom caused
this illness.”
Web-Posting #4
“I have noticed that Kratom has wonderful anti-anxiety, anti-depressant, painkilling, diuretic,
prolonged sexual intercourse, and even nasal decongestant qualities. It is my cure all. I have
noticed no detrimental effects from drinking it, and at any quantity. My body seems to tell me
that I have had all I need, once I have reached an awesome plateau of good feelings.”
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Web-Posting # 5
“I was hesitant submitting this story due to privacy concerns. About half an hour after trying
some of the extract I was overwhelmed with a sense I needed to lay down. Next thing I know, my
friend is standing over me on the kitchen floor trying to wake me up. It turns out I had convulsed
at the table and passed out. I was weak, disoriented and had trouble speaking. After laying there
for about five minutes, unable physically to do much, my friend tried to sit me up. I immediately
passed out again. At this point my friend took my pulse. I was running at between 35-40 beats a
minute, which is exceptionally low from my understanding. After a half hour I was able to stand
up and walk to the bathroom. Both he and I thought I was going to die. This was not fun or
enlightening.”

Web-Posting #6
“The usual opiate-like effects came on, but I was more euphoric than usual. The problem was I
couldn’t urinate; I tried to relax for ages but couldn’t piss and had to go back to bed. It was very
painful and distressing. I later woke up to find blood in my boxers. I had pissed out blood. By the
morning I had come down and with the help of a diuretic (tea) managed a normal piss. Naturally
this was very disturbing. We don’t know anything about the toxicity of kratom. Just because it’s
natural doesn’t mean it isn’t dangerous.”
1. In your opinion, how much will you harm yourself (physically or in other ways) if you…
No
Harm

Moderate
Harm

Great
Harm

…Use the herb kratom
ONCE OR TWICE
just to see what it is like?

1

2

3

4

5

6

7

…Use the herb kratom
OCCASIONALLY?

1

2

3

4

5

6

7

…Use the herb kratom
REGULARLY?

1

2

3

4

5

6

7

2. In your opinion, on a scale from 0 – 100%, how likely are you to harm yourself (physically
and in other ways) if you…
(Please write numbers in below. “0” means “no chance” and “100” means “definitely”)
…Use the herb kratom
ONCE OR TWICE
just to see what it is like?

____%
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…Use the herb kratom
OCCASIONALLY?

____%

…Use the herb kratom
REGULARLY?

____%

3. During the next 12 months, how many times do you think you will use the herb kratom the
next 12 months?
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)

Never
1-2 times
3-5 times
6-9 times
10-19 times
20-29 times
30-39 times
40 or more times
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APPENDIX M: EVALUATION OF WEB-POSTINGS
INSTRUCTIONS:
Below are 16 anonymous web postings. Each posting describes a real person’s experience using
over-the-counter cough and cold medication for the purposes of getting buzzed or high. The
“postings” were taken from a real website that provides information and personal experiences
regarding the use of many different substances.
Please read each web posting. After you read each posting, we will ask you to respond to a few
questions assessing your reactions to the experience described in each web posting.
Web Posting # 8: Cough and Cold Medication
Now I am always very careful with drugs that I take for the first time. I had read about cough
and cold pills and figured I could handle it. About 45 minutes later after taking some I started to
feel a little lightheaded and dizzy. After about an hour I began to feel nauseated and sick. I made
my way back to the bathroom and sat on the floor next to the toilet, hoping to throw up the pills.
By this time I was having trouble breathing, my throat felt tight and I was breathing heavily from
what I can remember. I went back over to my bed and lay there hallucinating. Every time I
closed my eyes I had vivid hallucinations. I think I saw God. I remember hearing things.
Suddenly, my cat jumped at my door and burst into my room. My heart raced, I think I almost
had a heart attack. It was the worst feeling ever. I just wanted it to go away. I wanted to sober
up. But that was not possible. By the time my mom got home I was feeling considerably better.
My mind had cleared, I was no longer hallucinating but I had a bad hangover.

1. We would like your opinion about the experiences described above. Please indicate how
well each of the following adjectives describes the above experience. Please respond by
clicking on the rating scale below:

Not at all

Moderately

Extremely

Intense

0

0

0

0

0

0

0

Good

0

0

0

0

0

0

0

Pleasant

0

0

0

0

0

0

0

Inviting

0

0

0

0

0

0

0

Bad

0

0

0

0

0

0

0

Scary

0

0

0

0

0

0

0

Unpleasant

0

0

0

0

0

0

0
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